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ABSTRACT 
There is no pharmacological treatment for obstructive sleep apnea (OSA) in clinical practice. 
The overall aim of this thesis was to investigate the effect of carbonic anhydrase (CA) 
enzyme activity on sleep apnea severity and blood pressure (BP) regulation in OSA. We 
explored the association between arterial standard bicarbonate (StHCO3
-), a proxy for CA 
activity, and apnea severity as well as hypertension status in a retrospective cohort of OSA 
patients (n=830, paper I). In a cross-sectional sleep clinic cohort (n=70), we explored the 
association between whole blood CA enzyme activity and OSA severity (paper II). 
Furthermore, we designed a randomized, placebo-controlled study to investigate the effect 
of pharmacological CA inhibition after zonisamide (ZNS) on sleep disordered breathing in 
overweight/obese OSA patients (n=42, paper III). Finally, the effect of CA inhibitor 
acetazolamide (AZT), continuous positive airway pressure (CPAP) or the combination thereof 
on sleep apnea and BP was investigated in a three-way cross-over study in 13 male 
hypertensive OSA patients (paper IV). Sleep disordered breathing was quantified by 
polysomnographic/polygraphic recording. Office systolic/diastolic BP (SBP/DBP) and vascular 
stiffness were assessed. Arterial/venous StHCO3
- was collected. In paper I, we found that 
arterial StHCO3
- was independently associated with apnea-hypopnea index (AHI) as the 
measure of OSA severity (p<0.001). In addition, arterial StHCO3
- was positively associated 
with both a hypertension diagnosis and DBP (p=0.007 and 0.048, respectively). In paper II, 
CA activity was associated with AHI, nocturnal hypoxemia as well as DBP (p=0.007, 0.011 and 
0.046, respectively). In paper III and IV, therapeutic intervention using ZNS and AZT, 
significantly reduced AHI by 33(39) % (placebo-adjusted) and 42(27) % (p=0.02 and 0.001, 
respectively). AZT reduced office BP in parallel with improvement of vascular stiffness 
compared to CPAP. In conclusion, our studies suggest an independent association between 
CA activity and OSA. High CA activity may represent a novel mechanism for development of 
hypertension in OSA. Drugs with CA inhibitory properties may provide a promising target for 
disease modifying treatment in OSA and its related comorbidities. 
Keywords: bicarbonate, blood pressure, carbonic anhydrase, hypertension, obesity, obstructive sleep 
apnea, vascular function  
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1 Sammanfattning på svenska 
 
Obstruktiv sömnapné (OSA) förekommer med en prevalens av 9 % respektive 24 % hos 
kvinnor och män i åldersintervallet 30-60 år. OSA är associerad med hjärt-kärlsjukdom, 
huvudsakligen hypertoni (HT), ischemisk hjärtsjukdom och stroke. OSA leder även till uttalad 
dagtidssömnighet, vilket har implikationer för trötthetsrelaterade olyckor och reducerad 
livskvalitet. Karbanhydraser (CA) är en familj av enzymer som katalyserar omvandlingen av 
CO2 till bikarbonat och protoner. CA har associerats med en rad fysiologiska och patologiska 
tillstånd som glukoneogenes, tumerogenes samt tillväxt och virulens av patogener. CA utgör 
därmed ett fundamentalt fysiologiskt reglersystem för upprätthållande av stabil syra-bas 
balans i olika vävnader. Denna avhandling studerar sambandet mellan CA aktivitet och 
svårighetsgraden av OSA och blodtryck. 
 
Delarbeten i avhandlingen omfattar epidemiologiska studier kring associationen mellan 
standard bikarbonat (StHCO3
-), som en surrogatmarkör för CA aktivitet, och svårighetsgraden 
av OSA och hypertoni. Vidare undersöktes sambandet mellan CA enzym aktivitet i helblod 
och OSA i en tvärsnittstudie hos 70 kliniska OSA patienter. I en randomiserad placebo-
kontrollerad studie studerades effekten av läkemedel med CA hämmande egenskaper 
avseende sömnapné hos OSA patienter (n= 42). Slutligen, analyserades effekten av CA 
hämning med läkemedlet acetazolamid på OSA såväl som blodtryck hos 13 manliga OSA 
patienter med etablerad hypertension. Metoder som implementerades i avhandlingen 
omfattade polysomnografi/polygrafi, blodtrycksmätning samt icke-invasiv arteriografi. 
 
Studierna visar att en ökad aktivitet av CA i helblod var associerad med en högre intensitet 
av OSA. Vidare kunde vi fastställa ett samband mellan standard bikarbonat (StHCO3
-) och 
såväl OSA som HT i en stor retrospektiv kohort (n=830). Vi kunde också visa att två 
läkemedel med CA hämmande egenskaper, zonisamid och acetazolamid, reducerade 
mängden OSA med 19-42 % hos patienter med måttlig till uttalad sjukdom.  
Behandlingseffekten, definierat som minst 20 % reduktion av AHI, uppnåddes av 70 % av 
behandlade patienter. Efter justering för följsamhet till behandling var effekten på AHI efter 
CPAP och acetazolamid inte signifikant skild. Patienter med hypertoni reducerade sitt 
blodtryck efter såväl zonisamid som acetazolamid. Trycksänkningen var direkt relaterad till 
en kärldilatation, uppmätt med icke-invasiv arteriografi.  
Vi har i dessa studier identifierat en ny möjlig farmakologisk princip för behandling av 
åtminstone en subgrupp av patienter med OSA. Denna nya behandling kan innebära en 
sjukdomsmodifierande dimension framför nu tillgänglig konventionell mekanisk terapi som 
exempelvis CPAP eller intra-oral skena. Framtida studier får utvisa i vilken omfattning denna 
nya behandlingsform kan användas vid sömnapnébehandling. 
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4 Abbreviations 
AASM 
AHI 
AF 
AZT 
BMI 
BP  
CA 
CAD 
CO2 
CSA 
CSR 
CPAP 
CV 
DM 
EDS 
ESADA 
ESS 
HF 
HR 
HT 
LG 
MSLT 
MWT 
ODI 
American Academy of Sleep Medicine 
Apnea-hypopnea index 
Atrial fibrillation 
Acetazolamide 
Body mass index 
Blood pressure 
Carbonic anhydrase 
Coronary artery disease 
Carbon dioxide 
Central sleep apnea 
Cheyne-stokes respiration 
Continuous positive airway pressure  
Cardiovascular 
Diabetes mellitus 
Excessive daytime sleepiness 
European Sleep Apnea Database 
Epworth sleepiness scale 
Heart failure 
Heart rate 
Hypertension 
Loop gain 
Multiple sleep latency test 
Maintenance of wakefulness test 
Oxygen desaturation index 
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OHS 
OSA 
PCO2 
Pcrit 
PG 
PSG 
MAP 
RCT 
SA 
SAA% 
SDB 
StHCO3
- 
T2DM 
UA 
Obesity hypoventilation syndrome 
Obstructive sleep apnea 
Partial pressure of carbon dioxide 
Pharyngeal critical pressure 
Polygraphy 
Polysomnography 
Mean arterial pressure 
Randomized controlled trial  
Sleep apnea 
Sleep apnea alleviation 
Sleep disordered breathing  
Standard bicarbonate 
Type II diabetes mellitus 
Upper airway 
ZNS Zonisamide 
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5 Introduction 
Obstructive sleep apnea (OSA) is a highly prevalent breathing disorder in the adult 
population with a variable degree of symptoms and comorbidities1. OSA tends to occur in 
different forms whereby some patients may suffer from dominant hypersomnia or 
symptoms of insomnia others may have no- or very discrete symptoms. The detailed 
pathophysiology of OSA is not fully understood and several different underlying mechanisms 
have been proposed. It is likely that some of these mechanisms represent separate 
phenotypic traits in the clinical population. For instance, recent attempts to sub-classify 
causes of upper airway (UA) collapsibility in OSA have provided models that include both 
structural and functional physiological characteristics2. OSA, or particular components of the 
disorder, is widely accepted to contribute to comorbidities such as cognitive dysfunction3, 4, 
metabolic disorders5-7 and cardiovascular (CV) disease8, 9. Longitudinal population studies 
and registry data from sleep clinic cohorts have demonstrated a considerable increase in 
mortality10, 11.   
Conventional therapies such as continuous positive airway pressure (CPAP) effectively 
reduce both OSA and symptoms related to the condition. However, CPAP treatment is 
frequently hampered by poor compliance which limits the therapeutic potential of the 
therapy12-14. Limitations also apply for other therapies such as intraoral devices and surgical 
interventions applied in OSA. Taken together, there is a need for new forms of therapy in 
OSA. Such therapies should address the improved understanding of the underlying 
pathophysiology in OSA which recently has emerged. An additional target for novel forms of 
therapy in OSA should not only address the mere breathing disorder in OSA but also 
comorbidities such as hypertension (HT), metabolic disease and/or obesity. 
 
5.1 Sleep apnea - definitions and criteria 
OSA is defined on the basis of recurrent events of partial (hypopneas) or complete (apneas) 
cessation of breathing in spite of respiratory efforts during sleep. The most frequently 
applied definitions and criteria are those published by the American Academy of Sleep 
Medicine (AASM)15. Apneic events are defined as complete (≥90%) reduction of the 
amplitude of the breathing signal whereas hypopneas are defined as a reduction of 
amplitude by ≥30%. Hypopnea event should be associated with a ≥3 % decrease of oxygen 
desaturation or an arousal15. The duration of events should be at least 10 seconds. The 
apnea-hypopnea index (AHI) reflects the number of events per hour of sleep and this metric 
is conventionally used to assess the occurrence and severity of the disease. According to 
current convention the OSA diagnosis is based on a combination of an AHI ≥5 n/hr plus 
symptoms (e.g. excessive daytime sleepiness (EDS)) or a recognized comorbidity (e.g. HT or 
diabetes). Alternatively OSA may be diagnosed based on the respiratory disorder alone 
(AHI≥15 n/hr). It should be noted that the AASM does not explicitly list other potential 
markers of OSA such as hypoxic events or arousals from sleep as tools for diagnostic 
assessment. However, several research studies have applied various measures of 
oxygenation (e.g. oxygen desaturation index (ODI) 3 or 4%, mean overnight saturation or 
minimum overnight saturation) to quantify severity of sleep disordered breathing (SDB)16, 17. 
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A frequently adopted clinical convention for classification of the OSA severity labels the 
condition as mild (5≤AHI<15), moderate (15≤AHI<30) or severe (AHI≥30). Diagnostic 
conventions such as those issued by the AASM also list both clinical conditions and 
symptoms that should alert health professionals on a possible sleep and breathing related 
conditions (Table 1).  
Table 1. Evaluation of clinical conditions and symptoms for the assessment of OSA (Adapted from the 
AASM) 
 
 
 
 
 
 
 
 
 
 
Central sleep apnea (CSA) 
Central sleep apnea (CSA) is a form of periodic breathing where apneas/hypopneas are 
followed by periods of hyperventilation. In contrast to OSA, central apneas (airflow cessation 
of ≥10s with ≥90% reduction in airflow amplitude) occur without an increase of intrathoracic 
pressure or apparent respiratory effort (Figure 1). Central hypopneas are scored according to 
criteria similar to those used for  obstructive hypopneas but without considering any evident 
snoring, paradoxical breathing, flatting of the nasal pressure flow or regard to the positive 
airway pressure flow signal15. Most forms of CSA appears to be associated with an impaired 
ventilatory drive in response to changes in the partial pressure of carbon dioxide (PCO2)
18, 19. 
Figure 1. Respiratory pattern of obstructive sleep apnea (right) and central sleep apnea (left) 
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Cheyne-Stokes respiration 
Cheyne stokes respiration (CSR) is a specific form of central respiratory events which is 
characterized by a crescendo–decrescendo pattern of the breathing signal. CSR occurs 
primarily during the non-rapid eye movement sleep and the cycle time (approximately 30-60 
seconds) is generally longer than that conventionally seen in various forms of OSA and CSA20, 
21. CSR is especially likely to occur during certain physiological situations such as high altitude 
sojourns and specifically during sleep at high altitude. Hence, unstable breathing may be 
elicited by alteration of the blood gas environment in combination with functional state. CSR 
appears to be more common in men compared with women and clinical studies have shown 
that CSR may be prevalent in 30-40% of patients with congestive heart failure22, 23. As with 
CSA, the mechanism by which hyperventilation leads to in fall in PCO2 is also reflected in CSR 
patients. In CSR, hyperventilation during sleep induces a reduction of the PCO2 (hypocapnia). 
Once this value reaches a level below the apneic threshold there is no stimulus to breathe 
and consequently a cessation of the respiratory drive and airflow24. Accordingly, patients 
with CSR appear to exhibit both daytime and night-time hypocapnia18 as well as  increased 
central and peripheral chemosensory responsiveness (increased controller gain)25, 26,27. An 
additional contribution to the appearance of CSR in patients with cardiac failure may be 
provided by the reduced functional lung-volume and delay in circulation time which signifies 
this patient group. Fluctuations in the chemosensory stimulus caused by the fluctuating  
blood gases leads to ventilatory instability21. 
 
5.2 Pathophysiology of OSA - cause of airway obstruction 
Airway obstruction in OSA generally occurs at the level of the soft palate or at the level of 
the tongue28. Static, as well as anatomical and dynamic neuromuscular factors appear to 
contribute. Static factors include components such as airway surface adhesion, posture of 
the neck and jaw and gravity. OSA will worsen in the supine sleeping position in most 
patients and many patients have strictly position dependent OSA29. Anatomic factors 
including tonsillar hypertrophy, large tongue volume, prominent soft palate or lateral 
pharyngeal walls30, abnormal positioning of the mandible may, due to reduced volume of 
the UA, predispose to airway collapse31. In particular parapharyngeal fat pads may 
contribute to obesity related OSA. The dynamic component is provided by neuromuscular 
activity in the UA which is known to physiologically decrease during sleep32, 33. The aperture 
of the UA is determined by the transmural pressure, which results from the pressure in the 
airway lumen and the pressure in the surrounding tissue34. A reduction of transmural 
pressure will bring the airway to a critical point referred to as the pharyngeal critical 
pressure (Pcrit). For instance, a recently introduced method for intermittent hypoglossal 
nerve stimulation during sleep is known to evoke a genioglossal muscle contraction which 
results in a reduction of UA collapsibility35.  
The duration of the obstructive breathing events is determined by the time that the Pcrit is 
exceeded and Pcrit has been used clinically as a composite measure of airway collapsibility in 
patients with sleep apnea (SA)36-38. The arousal that occurs at the end of the 
apnea/hypopnea is an important determinant for the re-opening of the UA when other 
restoring mechanisms have failed33. However, not all apneas/hypopneas are terminated by 
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an identifiable arousal and in such cases there may be other compensatory mechanisms 
such as increased genioglossus activity39,40. Eckert et al. (Figure 2) have proposed that 
approximately one third of OSA patients have a low threshold which may contribute to an 
oscillation in ventilator drive which acts to self-sustain apneic events2. This mechanism may 
be particularly important in various forms of CSA, but also in OSA. Hence, patients with a low 
arousal threshold may benefit from an elevation of threshold and this has been described 
after administration of a benzodiazepine in patients with OSA41. 
 
Figure 2. Different pathophysiological overlapping mechanisms considered in OSA (adapted from 
Eckert et al.
2
) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The central nervous control of breathing appears to play an important role in all forms of 
apnea and instability may lead not only to central apnea but also to the development of 
OSA. This may be exemplified by experiments demonstrating that hypercapnia may prevent 
OSA events. Hyperventilation-induced hypocapnia, as seen at resolution of apneic event, 
leads to reduced pharyngeal dilator activity and limitation of inspiratory flow34. Sudden 
arousal from sleep (which occurs at the end of the apneic episode) increases the likelihood 
of a relative hyperventilation. The degree of hyperventilation is determined by the gain of 
the respiratory system in response to chemosensory stimulation (loop gain, LG). Prevailing 
theories suggest that a steeper LG will contribute to a higher risk of rendering the ventilatory 
system in a state of sustained oscillation42-44. LG has therefore recently emerged as a 
possible factor that reflects the (in) stability of the ventilatory system. An elevated LG  could, 
according to some researchers be present in approximately one-third OSA patients2. 
Accordingly, a high LG has been associated with increased OSA severity and low LG is 
associated with stable breathing44-47. Supplemental oxygen and certain pharmacological 
interventions (e.g. acetazolamide (AZT)) reduced LG and AHI in small clinical trials with pre-
selected high LG OSA patients48-50. 
The proneness of airway collapse during various static conditions, in combination with the 
complex interplay between anatomical and neuromuscular will determine the actual clinical 
phenotype of the OSA patient. Importantly, existing data and pathophysiological models do 
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not fully explain why factors such as sex, age, and ethnicity influence the prevalence of this 
disorder51. The apparent combination of various factors in OSA has been addressed in a 
recent model of SA which propose that different degrees of overlap between mechanism 
will occur (Figure 2)2. From this model it is evident that overlap is very common and that 
anatomical factors alone may be present in as many as 80% of patients with OSA. Other 
mechanism including ineffective UA muscle capacity, low arousal threshold and high LG may 
contribute to variable extent. 
 
5.3   Epidemiology of OSA 
OSA (defined as AHI≥5) is a common finding in the general adult population. The reported 
prevalence ranges between 17 and 24% in men and between 5 and 17% in women1,52-56.  A 
recently published study by Heinzer and co-workers reported an even higher prevalence of 
OSA in men (84%) and women (61%)57. These high prevalence numbers have sparked a 
discussion on the validity of current thresholds for OSA diagnosis and prevalence. In fact, the 
most liberal diagnostic criteria for OSA do not appear to reflect any association with 
comorbid symptoms or outcome in OSA. Instead, longitudinal registry data  suggests that the 
prevalence of for instance CV comorbidity and outcome appears to increase more distinctly  
at an AHI threshold of approximately 1558. The prevalence numbers are also affected if 
symptom criteria are introduced. The most common symptom is daytime sleepiness and the 
prevalence of symptomatic OSA (AHI≥5 combined with EDS) is reported to vary between 3 
and 18 % in men and between 1 and 17 % in women59. 
 
5.4 Risk factors for OSA 
Age 
Several studies have shown that the prevalence of OSA linearly increases with age52,56. 
However, the age association appears to plateau around the age of 60 years51,53. The 
mechanism behind this non-linear association may be explained by altered  anatomical and 
physiological features in parapharyngeal structures60. The prevalence of OSA appears to 
decrease after 65-70 years of age in both men and women56.  
Gender 
OSA appears to be overrepresented in men with a 2:1 ratio in the general population1,52-56. 
However, recent data from a large European study suggests that this ratio may be in the 
order of 3:1 in clinical cohorts61. There are several potential explanations for the different 
OSA prevalence in men and women including for instance differences in UA structure and 
anatomy, hormonal status and body fat distribution62-68. However, the lower proportion of 
women in the clinical setting suggests that OSA may be underdiagnosed among women69,70. 
In fact, the vast majority of sleep research conducted up to mid-1990 were primarily 
conducted on the male population most likely due to neglect71. 
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Obesity 
Obesity is considered to be one of the strongest risk factors for OSA1,31,35. Approximately 
50% of patients seen at European sleep centres had a body mass index (BMI) above 30 in the 
European Sleep Apnea Database study7. Longitudinal data shows that even moderate weight 
gain, in the order of 10% or 10 kg, may induce a moderate to severe OSA in patients without 
OSA at baseline. Weight gain may also worsen pre-existing OSA72,73.  
The detailed mechanisms behind OSA development in obesity are still largely unknown. A 
reduction of pharyngeal size and aperture due to local fat distribution77 provides an evident 
explanation but other mechanisms related to breathing dynamics in the supine position29, 
redistribution of body fluid to the UA tissue74 and chemosensory attenuation associated with 
reduced leptin sensitivity75 have also been proposed. However, in spite of this strong 
association between obesity and OSA it should be noted that approximately one third of 
patients with OSA are not obese. Hence, pathophysiological mechanisms other than those 
related to anatomical changes appear to be operational in many cases.  
 
Nasal obstruction and craniofacial anatomy 
Small experimental studies in healthy normal subjects have demonstrated an increase of 
apneas and arousals following nasal occlusion76,77. Other larger studies have confirmed nasal 
obstruction as an independent risk factor for snoring and OSA78,79. Moreover, OSA patients 
with chronical rhinitis were twice as likely to have moderate to severe OSA in comparison to 
patients without nasal symptoms80. 
Narrow UA and increased UA collapsibility as consequence of specific craniofacial features 
and characteristics have been associated with OSA development81. Increased mandibular 
body length and thickened lateral pharyngeal muscle wall appear as the strongest 
craniofacial predictors for OSA28,82. 
Genetics 
Family members of OSA patients are more susceptible to the disorder83 with the genetic risk 
factors being attributed to abnormalities in the control of breathing, obesity as well as 
craniofacial features84-87. Genome-wide scan analyses based on data from the Cleveland 
Family Study have identified candidate genes (chromosomes 1p, 2p, 12p, 19p) that are 
associated with AHI in OSA patients86.  In addition, data from the same cohort found 
associations between single-nucleotide polymorphisms on chromosomes 8p21.3 and 
8q24.188. However, the association between the candidate genes and AHI was weakened in 
both studies after introducing BMI in the model. In fact, the heterogeneity and complexity of 
OSA and its symptoms make it difficult to find one unison genetic factor. Hence, genetic 
analysis in large cohorts of well characterized OSA patients and controls are necessary to 
identify the potential genetic background of OSA.  Less frequent risk factors and causes for 
OSA have been reported including acromegaly89, gastro-oesophageal reflux90 and 
hypothyroid function91. 
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5.5 Diagnostic tools for OSA 
The Berlin questionnaire has been used as a validated screening tool with high sensitivity 
(0.80) and specificity (0.76) for the identification of patients at risk for OSA92-94. The 
questionnaire assesses snoring, daytime sleepiness and HT as well as anthropometric 
information including age, gender, height, weight and neck size. Validation studies using  
polysomnography (PSG) suggest that the Berlin questionnaire has a moderate sensitivity and 
low specificity at identifying OSA patients with respiratory disturbance index >5 n/hr95.  
Other validated screening tools include the STOP and the STOP-bang questionnaires. The 
STOP questionnaire assesses four domains including snoring, tiredness, witnessed apnea and 
high blood pressure (BP). STOP has a moderate sensitivity and specificity (0.66 and 0.60, 
respectively) for OSA (defined as AHI≥5)96. The STOP-bang questionnaire has added four 
domains including age, gender, BMI and neck size to the domains assessed in the STOP-
questionnaire. The STOP-bang is accompanied by a high sensitivity (pooled 0.90) and low 
specificity (0.49) for detection of OSA (defined as AHI≥5) in various sleep clinic populations97. 
The Epworth sleepiness scale (ESS) and the Functional Outcome of Sleep Questionnaire 
(FOSQ) are frequently used questionnaires to assess subjective daytime sleepiness or the 
impact of sleepiness on multiple activities of everyday living, respectively98,99. The ESS 
reflects the propensity of falling asleep during a wide range of daily activities and a total ESS 
score ≥10 is generally considered to signal EDS. The FOSQ questionnaire is subcategorized 
into five different domains including general productivity, intimate and sexual activity, social 
outcomes, vigilance and activity level.   
The Multiple sleep latency test (MSLT) and the Maintenance of wakefulness test (MWT) are 
used in the clinical setting to objectively assess EDS or associated alertness in OSA100, 101. In 
addition to assessment of symptoms in EDS, the MWT and MSLT are sometimes also used to 
evaluate the effectiveness of ongoing OSA therapy. The MSLT is performed in a dark room in 
which the patients are asked to try to go to sleep during five 20-minutes naps with two hour 
intervals. The test measures the patient’s propensity to fall asleep. The MWT on the other 
hand measures the patient’s ability to stay awake during monotonous conditions (i.e. in a 
dark and silent room). The test consists of four sessions of 40 minutes with each session 
separated by a two hour period. According to recent guidelines a mean sleep latency of <8  
minutes during the MSLT is used to define EDS in SA patients102. Both the MSLT and MWT 
are considered to be very time consuming for the patient as well as for the sleep technician. 
The current AASM classification of instruments used for diagnosis of SDB ranks diagnostic 
instruments into level I (Standard technician-attended PSG in the laboratory setting), level II 
(Comprehensive portable PSG), level III (Modified portable polygraphy (PG)) and level IV 
(Continuous single or dual channel) devices. The level I and II versions of PSG include 
electroencephalography, electrooculogram, electromyography (chin and leg), airflow, 
oxygen saturation, respiratory effort belts, and electrocardiography (heart rate (HR))103. 
Supervised level I PSG is considered to be time-consuming for the clinicians and patients and 
hence accompanied by less availability and higher cost. Level II PSG in the home-setting 
(ambulatory PSG) provides a reliable evaluation although the patient cannot be continuously 
supervised during the recording104. Data from a large scale population study suggested that 
reliable sleep scoring could be obtained from more than 98.6% of the recordings105. 
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PG (level III and IV devices) is currently the most frequently used device class for the routine 
evaluation of suspected SDB, particularly in the Nordic countries. Signals recorded in the 
level III devices include airflow (nasal cannula), respiratory effort and oxygenation (pulse 
oximetry)103. Data from the European Sleep Apnea Database (ESADA) cohort suggest an 
approximately 1:1 usage ratio between PG and PSG in European patients investigated for 
OSA at academic centers106. The ESADA cohort also concluded that the AHI score, as 
evaluated by PG, was approximately 30% lower than that obtained in patients investigated 
by PSG106. As PG uses total recording time as the time basis, rather than actual sleep time, 
for the calculation of the AHI there is a dilution of the index.  
 
The AASM has reviewed and produced standards for diagnostic recordings in OSA. The 
current recommendations reflect a global trend away from complex methodologies towards 
simpler and frequently portable techniques103. This development reflects the fact that less 
intrusive methods provide a recording that better resembles the regular sleeping conditions 
and that home recordings may better mimic the habitual sleep environment. It is also 
recognised that less demanding methods provide a more cost effective evaluation in 
conventional SA patients. However, a less detailed investigation might lead to a less well 
characterised condition and a difficulty for differential sleep related diagnoses such as motor 
disorders or parasomnias. 
 
The objective and subjective measurements applied for the diagnosis of OSA is accompanied 
by the physician’s evaluation of medical history, laboratory evaluation and anthropometric 
data. There are currently no systematically used biomarkers for the diagnosis or severity 
assessment of OSA. Such tools, particularly if they are associated with high sensitivity and 
specificity for one or more key components of the sleep and breathing disorder, would 
significantly influence the methods and practices of sleep medicine107. 
 
5.6 Clinical symptoms and consequences of OSA 
Excessive daytime sleepiness 
EDS is a hallmark symptom in OSA.  The development of EDS in OSA is conventionally linked 
to the phenomena of respiratory arousals leading to sleep fragmentation and nocturnal 
hypoxemia associated with the apneic events108,109. However, this relationship has not been 
fully supported by recent larger studies110-112. Daytime sleepiness has been independently 
associated with AHI, EDS increases with OSA severity as well as  it is more frequently 
observed in the female population1,110. Several studies have shown that CPAP is efficient in 
reducing EDS, particularly in patients with moderate to severe OSA113-116. 
Metabolic disease 
Several recent epidemiological and clinical studies support an association between either 
insulin resistance or Type 2 diabetes mellitus (T2DM) and OSA and this association is, in 
several studies, partly independent of conventional risk factors such as obesity5,117-119. An 
analysis of  data from the ESADA cohort suggested an increased risk of concomitant T2DM in 
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OSA patients7 (Figure 3) supporting a contributing role of OSA in the development of 
T2DM120.   
Figure 3. Prevalence of type II diabetes across OSA severity classes in the ESADA cohort (Adapted 
from Kent et al.
7
). 
 
 
Other studies focusing on glycaemic control have demonstrated an independent association 
between OSA and impaired insulin or glucose metabolism5,118,121. The association was linked 
to both the intensity of OSA as well as the extent of nocturnal hypoxemia5,122-124. 
Intermittent hypoxia, increased oxidative stress as well as sleep fragmentation have 
therefore been proposed as pivotal mechanistic links behind the associations between OSA 
and impaired glycaemic control125-127. OSA therefore appears to constitute a risk factor for 
T2DM as well as an exceptionally frequent comorbidity with adverse effects on glycemic 
control128-130. 
Several studies have addressed the effects of CPAP on insulin resistance and glycaemic 
control in non-diabetic and diabetic OSA patients131,132. While some studies showed weak 
effects on the homeostasis model assessment index in non-diabetic or diabetic patients 
others did not129,133-135. There are several potential explanations for the variable effects of 
therapy. A more recent study suggested that the extent of glycaemic control prior the CPAP 
may predict the results after treatment136. In addition the effect of CPAP may be more 
evident in lean compared to obese diabetes mellitus (DM) patients132. In this context it is 
interesting to note that CPAP therapy may have negative effects on body weight presumably 
due to reduction of energy metabolism137. Hence, future intervention studies on OSA need 
to incorporate simultaneous diet counselling. It is also possible that poor CPAP compliance 
(e.g. less than 4 hours per night) may explain at least in part the weak effects on glucose 
metabolism in some of these OSA treatment studies.  
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Hypertension 
The relationship between OSA and HT has been well established in several population-based 
cohorts53,138-140. In fact, recent Joint National Committee (JNC-8) guidelines have positioned 
OSA as common cause of behind HT development141. Longitudinal data from the Wisconsin 
sleep cohort reported a three-fold increased likelihood of HT prevalence when comparing 
OSA to non-OSA patients9. Moreover, there is a high prevalence (between 35-70%) of HT in 
OSA patients and HT increases independently across OSA severity classes105,142,143. HT 
appears to be overrepresented in middle-aged OSA patients when the cut-off is set at <60 
years56,144. Epidemiological data have shown an increased risk of HT in OSA patients with 
self-reported EDS145,146. Furthermore, OSA is highly prevalent in patients with drug resistant 
HT where the prevalence has been reported to be as high as 70%147-149. 
The pathophysiological mechanisms behind HT development in OSA appear to be 
multifaceted. The occurrence of repetitive apnea events induces an increased night/daytime 
sympathetic activity during night and the autonomic activation is associated with elevated 
BP in OSA150-152. Some studies suggest that hypoxia during apneas may be a particularly 
strong contributing factor to the sympathetic response153,154. This is also in line with  findings 
from the large ESADA cohort suggesting  that HT prevalence may be more strongly 
associated with intermittent hypoxia than apnea events per se155. The repetitive cycles of 
hypoxia/re-oxygenation, as seen in OSA, may also lead to impaired endothelial function as 
evidenced by studies demonstrating reduced levels of nitric oxide and vasodilation156-160. 
However, sleep fragmentation161, increased intrathoracic pressure162,163, a dysfunctional 
renin-angiotensin system and a reduction of the baroreflex threshold164 have also been 
proposed as potential mechanisms behind BP elevation and subsequent HT development in 
OSA.  
CPAP has been shown to modify and attenuate several of the above mentioned potential 
pathophysiological mechanisms in OSA. However, the effect of CPAP on BP in unselected 
patients with OSA is proportionally weak165. A recent large randomized controlled trial (RCT) 
reported a weak, however significant, effect on DBP -0.7 (95% CI=-1.4 to 0.0) when 
comparing CPAP treated (n=1346) to non CPAP treated (n=1341) OSA patients13. The effect 
size is approximately 2-3 mmHg according to meta-analysis and the strongest effects of CPAP 
with regards to BP reduction are observed in OSA patients with pre-existing antihypertensive 
medication and in patients with resistant HT166-168.  
Coronary artery disease  
Coronary artery disease (CAD), defined as angina pectoris or myocardial infarction, have 
been reported as frequent as 40% in patients with OSA8,16,169,170. The reciprocal association 
has also been shown in a controlled study171. Cross-sectional data from the Sleep Heart 
Health Study reported a 1.27 fold increased risk of CAD among OSA8 patients. A subsequent 
prospective study found an almost five times higher incidence of CAD in OSA patients when 
compared with OSA-free individuals172. CPAP treatment has been associated with a risk 
reduction of CAD in some but not all studies58,172. Indeed, the mechanisms that potentially 
might link OSA with CAD remain to be elucidated. Several routes potentially linking periodic 
hypoxia and vascular inflammation has been described173. A recent interesting study 
suggests that serum from SA patients may induce inflammation in coronary endothelial cells 
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when a novel endothelial biosensor approach (the serum cumulative inflammatory potential 
assay) was used174. 
Arrhythmias 
Atrial fibrillation (AF) is a common arrhythmia in clinical practice and associated with 
increased CV morbidity and mortality175,176. Several of the conventionally considered risk 
factors for AF such as age, HT, DM, obesity, CAD and congestive heart failure overlap with 
those considered in OSA177. In this context it is also evident that consequences of OSA, 
including periodic hypoxia and hypercapnia, shifts of intrathoracic pressure, increased 
autonomic nervous system activity and sudden BP swings may increase the risk of AF in 
patients with OSA178.     
Recent studies have reported an increased prevalence of OSA among patients with AF and 
the strength of the association was related to the severity of OSA179-181. The odds ratio for AF 
in these studies ranged between 2.19 and 17.9. AF is independently associated with OSA and 
the risk is increased with by a factor of four when comparing severe to non-OSA patients182. 
Other studies suggested an increased incidence of AF in OSA183. Meta-analysis data in 
patients following catheter ablation due to recurrent AF show that untreated OSA increased 
the risk for recurrence of AF by 25% when compared with CPAP treated patients 184. 
Furthermore, additional data from meta-analysis that included 8 studies that CPAP 
treatment was associated a 44% reduced risk of AF recurrence185. There is increasing 
consensus among cardiologists that screening and early detection of OSA may have 
important health beneficial effects. In fact, recent study by Abe et al. showed that CPAP 
treatment significantly reduced occurrence the OSA-associated arrhythmia risk amongst a 
sub-population of 316 Japanese OSA patients186. 
OSA has also been considered in ventricular arrhythmias. Early data have suggested that 
ventricular tachycardia and premature ventricular contractions in addition to sinus arrest, 
bradycardia, atrioventricular cardiac block were associated with SDB and occurred primarily 
during sleep187. A recent meta-analysis on ventricular arrhythmias has concluded there is 
insufficient reliable data to explore the association between OSA and ventricular 
arrhythmias 188.  
 
Stroke 
Epidemiological studies suggested an independent association between OSA and stroke8,10, 
189. Conversely, there is a high prevalence of OSA (44-72%) in stroke patients190. More severe 
OSA (baseline AHI cut-offs AHI ≥20 and ≥30) increased the risk of stroke substantially, 
independent of potential confounding factors10,191,192. Valham et al. reported that the 
incidence of stroke increased in a OSA severity-dependent manner with a four-fold risk 
increase in odds-ratio when comparing severe OSA to non-OSA193. A recent meta-analysis 
based on data from six prospective studies reported a two-fold increase of stroke when 
comparing severe OSA (AHI>30) to non-OSA (AHI<5) patients194. In addition, CSA has been 
associated with an increased risk of stroke in SA patients195,196. There is inconsistent data 
when it comes to a potentially beneficial effect of CPAP on stroke risk in OSA patients. 
Whereas population based cohort studies have pointed to a reduced risk after CPAP most 
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RCT’s have failed to replicate this finding13,197,198. However, an ad-hoc analysis of the SAVE-
study suggested a possible beneficial effect of CPAP on stroke incidence13. Despite this, 
guidelines for stroke prevention recommend CPAP treatment as acute treatment following 
stroke, especially in patients with comorbid SA199.   
Congestive heart failure 
The association between heart failure (HF) and SDB have been established by several 
studies200-202. Shahar et al. reported a strong association between HF and SDB in cross-
sectional data from Sleep Heart Health Study8. The relationship these two disorders appear 
to be stronger in patients with HF-CSA203.  Moreover, OSA as well as CSA has been reported 
independent contributing factors behind an increased mortality risk amongst HF patients204, 
205. Both short/long term studies have suggested that CPAP therapy improves systolic BP, 
cardiac function as well as reduces the risk of mortality in OSA patients with HF206-208. 
Whether CPAP therapy may exhibit similar positive treatment effects in HF patients with CSA 
remains inconclusive209,210. A more recent controlled study in CSA-HF patients (n=1325) 
reported an increased risk of CV death (hazard ratio 1.34 [95% CI 1.09, 1.65]) in patients 
treated with adaptive servo-ventilation when compared to controls211. 
Mortality 
Early studies addressing long term outcome and mortality in OSA suggested an independent 
association between OSA and increased mortality. Levy et al. reported that SDB was an 
independent predictor for mortality amongst 1622 patients212. More recent evaluation of 
the influence of OSA on mortality in large cohorts suggested a 2.87 fold increase in mortality 
during a 12-year follow-up in those with untreated severe OSA (AHI≥30 events/hr)58. CPAP 
was associated with a normalization of mortality rate. This study was corrected for potential 
confounders. A subsequent study with a similar design was the prospective Sleep Heart 
Health study which showed a two-fold increase (hazard ratio 2.09 [95% CI 1.31–3.33]) in 
middle-aged men with moderate to severe untreated OSA patients when compared to non-
OSA patents213. The lower absolute difference in mortality between those with and without 
OSA in this study has been explained by a higher mean age. An even higher influence of OSA 
on mortality was reported in the Wisconsin Sleep Cohort with a (adjusted) all-cause 
mortality (hazard ratio 3.8 [95% CI 1.6 - 9.0]) in severe vs non-OSA patients and this increase 
was dose-dependent11. Several of these studies suggest that comorbid vascular disease (e.g. 
stroke, acute myocardial infarction, acute and chronic ischemic heart disease, AF, sudden 
cardiac arrest, cardiac dysrhythmias, cardiomyopathy, and pulmonary HT) may further 
increase mortality although this possibility needs to be confirmed in controlled trials. In fact, 
the presence of OSA increases the mortality rate in patients suffering from CV disease such 
as stroke or CAD10,17 58,189,214.  
All studies cited above are non-randomized. In fact there may be a possible ethical concern 
with regard to long term RCTs in OSA, particularly as comorbidities including EDS could 
increase the risk for motor vehicle accidents in those randomized to usual care215,216.  
Although CPAP has been shown to attenuate the mortality risk in OSA, recent data from the 
randomized controlled SAVE-study could not confirm this association as there was no 
significant difference between CPAP and non-CPAP users with regard to hard CV endpoints13. 
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However, the study was compromised by a number of factors including a low use of CPAP in 
the treatment group, which makes the overall generalization of the study more difficult. 
 
5.7 Current mainstay of OSA therapy 
Continuous positive airway pressure (CPAP) 
CPAP is widely considered as the first line therapy in OSA (Figure 4)217,218. CPAP provides a 
constant or variable positive airflow, which acts to splint the UA thereby preventing UA 
collapse. CPAP treatment has proven to be efficient in the reduction of OSA symptoms 
including objective and subjective daytime somnolence, as well as the improvement of 
cognitive function and quality of life13,116,219. The relative efficacy of CPAP seems to be more 
pronounced in patients with moderate to severe OSA. The overall efficiency of CPAP is in 
many cases limited by adherence to therapy which has been reported to be as low as 50% 12, 
14, 220. 
CPAP appears to have a relatively modest effect on BP in unselected OSA patients221. Meta-
analysis in the area has suggested that CPAP significantly reduces BP and risk of CV events in 
OSA patients with moderate-to-severe disorder and comorbid arterial HT58, 221-223. The effect 
of CPAP on BP seems to be more pronounced in those with severe disorder and more severe 
HT224. Two recent randomized control studies could not confirm any beneficial effect of 
CPAP on CV endpoints including stroke, ischemic heart disease or death in patients with OSA 
and HT13, 225.  
Figure 4. Continuous positive airway pressure device (left) and mandibular device (right). 
 
 
 
 
 
 
 
Mandibular devices 
Mandibular advancement devices (Figure 4) are currently used for treatment of OSA226. They 
have been considered in most countries as useful treatment alternatives for patients with 
mild-moderate OSA and patients not tolerating CPAP. This particular group is considerable as 
a consequence of  impaired long-term compliance and tolerability with CPAP227. Mandibular 
devices increase the UA cross sectional diameter and patency thereby reducing UA 
collapsibility228. Several studies have shown that these devices reduce OSA as well as 
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subjective and objective sleepiness229-231. Furthermore, mandibular advancement devices 
have been shown to reduce BP in prospective uncontrolled studies230,232,233. The overall 
effect on OSA, in terms of AHI reduction, of these devices is less pronounced than that 
obtained by CPAP but acceptance rates are usually higher234.  
 
Dietary weight counselling and bariatric surgery 
Given the strong association between obesity and OSA, as shown in numerous studies1,8,235, 
dietary and weight counselling is currently an under-utilized treatment modality in OSA236. 
Weight loss programs that include dietary counselling have been shown to lead to 
improvement of OSA, and to reduce daytime sleepiness and BP237,238. A controlled study by 
Johansson et al. using low caloric diet found that weight-loss was associated with significant 
improvements in OSA severity and EDS in obese patients with moderate to severe OSA238 
(Figure 5). 
Figure 5. Effects of low-caloric diet and weight loss in moderate to severe OSA patients (Adapted by 
Johansson et al.
238
) 
 
 
 
 
 
 
 
 
 
 
Bariatric surgery is considered to be an effective method for management of obesity and 
obesity related comorbidities (e.g. HT and DM) compared to non-surgical interventions239. 
Prospective data from the Swedish Obesity Study concluded that bariatric surgery was 
associated with marked reductions in reported apneas and symptoms of OSA (e.g. EDS)240. In 
addition, meta-analysis data from 12 studies, assessing OSA by PSG, reported an overall 
mean BMI reduction by -18 kg/m2 units and accompanied by mean AHI reduction of -38 
events/hr241. Bariatric surgery may be considered in obese individuals with a BMI in excess of 
35 kg/m2 who failed to reduce weight by conventional methods242,243.  
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Other surgical treatment 
Most surgical procedures for OSA aim to modify the anatomy of the UA. 
Uvulopalatopharyngoplasty (UPPP) is conventionally considered as an established method 
for OSA treatment244. The overall aim with UPPP is to enlarge the UA diameter. However, in 
unselected cases the procedure is accompanied by a high failure rate (approximately 
60%)245. A recent controlled study which used stringent criteria for patient selection 
reported a considerably higher success rate suggesting that this method may be considered 
in carefully selected cases246. Other proposed surgical treatment methods include nasal 
surgery. This method has been considered particularly useful in CPAP failure patients, 
particularly those cases where CPAP use is restricted by obstruction of the nasal airway. 
Nasal surgery may thereby increase adherence to pre-existing CPAP treatment247, 248. 
However, as the case with UPPP, nasal surgery has limited effect on OSA intensity249. Finally, 
a recently introduced method for intermittent stimulation of the hypoglossal nerve during 
sleep evokes a genioglossal muscle contraction which prevents UA collapsibility during sleep. 
Clinical data suggest that this method induces a reduction of the AHI in the order of 50% in 
preselected groups of patients with symptomatic OSA35,250. These effects persist even over 
time, but selection of patients is essential and those criteria are not very well defined yet. 
Pharmacological treatment 
Given the limitations associated with several of the treatment modalities used in OSA, there 
is a need for a pharmacological form of therapy. This is also evident in view of the 
considerable pathophysiological heterogeneity that characterises unselected patients 
referred in the sleep medicine clinics251. Several smaller trials have investigated the effects 
of postulated pharmacological remedies in OSA but were in general accompanied by small 
effect sizes and no conclusive results in terms of OSA improvement251,252.  Such trials include 
pharmacological agents such as gamma-aminobutyric acid and glutamate agonists, sex 
hormones, benzodiazepines glutamate, compounds modulating serotonin activity and 
theophyllines251. 
However, some more convincing results have been produced for pharmacologically induced 
weight reduction. For instance, an uncontrolled study of sibutramine, used for weight loss,  
in combination with weight counselling resulted in a mean BMI loss of 2.4 kg/m2 and a 36% 
reduction of AHI253. This combination of effects may be particularly beneficial in overweight 
OSA patients with a comorbid metabolic disorder253,254. Whilst sibutramine was withdrawn 
from the market due to severe CV adverse events  there are other interesting drugs that may 
be considered255.  
A formulation containing the combination of the appetite-suppressant drugs phentermine 
and topiramate induced a significant weight reductions (-10%) and there was an associated 
substantial decreases in AHI (approximately -70%) in obese patients with moderate severe 
OSA in a more recent randomized placebo controlled trial256 (Figure 6). In addition, 
significant improvements were also found in nocturnal oxygen saturationSpO2 and office BP. 
Long-term data on his particular formulation have demonstrated that a dose-dependent 
sustained weight loss may be achieved and there was an associated improvement of CV and 
metabolic variables in the obese patients in the study257. Another recent development is the 
GLP-1-analog (glucagon-like peptide) liraglutide which is indicated predominantly in T2DM. 
The clinical development program provided support for a reduction of body weight as well 
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as moderate improvement of SA resulting in the first label for obesity treatment in obese 
OSA patients defined as an BMI cut off of ≥27 kg/m2 258. 
Figure 6. The effects on weight and AHI following phentermine/topiramate treatment (adapted 
from Winslow et al. 
256
) 
 
 
 
 
 
 
 
 
 
 
Other recent studies have dealt with compounds that inhibit the enzyme acetylcholine 
esterase. A reference inhibitor of acetylcholine esterase, physostigmine, was associated with 
a 21.4% reduction of AHI and an improvement in minimum nocturnal SpO2 by 8.7% in a 
placebo controlled single night study259. Another available inhibitor of ACE, donepezil, was 
also shown to significantly improve AHI, mean and minimum SpO2 and EDS in patients with 
moderate to severe OSA  in a short term RCT260. The effects were particularly pronounced 
during REM sleep. However, more recent controlled trials failed to confirm the beneficial 
effects of donepezil on OSA261 (Hedner et al, unpublished data).  
 
 
5.8 Carbonic anhydrase - background and physiology 
Carbonic anhydrase in health and disease 
The carbonic anhydrase (CA) enzyme exists in at least 16 different isoforms (CA I-XVI) and is 
classified into 4 groups based on the localization (cytosolic, mitochondrial, secreted, 
membrane linked) in mammals262. The structure and function of this enzyme has been 
extensively studied following its initial discovery in red blood cells in 1932263, 264.  
Figure 7. Main chemical reactions catalysed by carbonic anhydrase 
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CA catalyses the conversion of CO2 to bicarbonate and protons (Figure 7). This reaction is 
slow but the presence of CA accelerates the process by a factor of 106. Hence, the enzyme 
plays a pivotal role not only for the regulation and maintenance of the acid-base 
homeostasis (pH), but also for the transport of CO2 (mainly via red blood cells) between 
tissues as well as in response to respiration263, 265. Bicarbonate production, pH regulation, as 
well as water balance controlled by CA, is vital to the function of several tissues. 
Dysfunctional CA activity has been associated with conditions like low gastric acid secretion, 
renal failure and glaucoma262,266. The enzyme is also involved in reactions that require 
bicarbonate as a substrate such as glukoneogenesis, lipogenesis, and ureagenesis267. Other 
processes where CA is involved include cancerogenesis (or tumorigenesis) as well as growth 
and virulence of pathogens268,269.  
Due to the widespread expression of the enzyme in human organs and tissue the biological 
principle has become target for various compounds with CA activating or inhibitory 
properties. For instance, the CA inhibitor dorzolamide has been used as an anti-glaucoma 
agent which reduces the intra-ocular pressure as a consequence of decreased bicarbonate 
level and aqueous humour production266. CA inhibitors have also been considered as 
anticancer/anti-metastatic treatment as various CA iso-enzymes are overexpressed in 
hypoxic tumour cells. Blocking the CA enzyme capacity to produce protons leads to a less 
acidified environment in which tumour growth and proliferation rate is reduced270. 
CA has also been targeted in obesity research271. RCT´s using CA inhibitors like zonisamide 
(ZNS) and topiramate have shown prominent weight reduction in obese patients256,272. The 
mechanisms behind the weight loss effect may in part include a modulation of de-novo 
lipogenesis267. Moreover, the expression of CAIII in subcutaneous adipocytes from obese 
patients was reduced (Jernås et al. unpublished data). It was hypothesized that CAIII 
maintains a scavenger role by a reduction of the amounts of free radicals in the fat cell.  
Carbonic anhydrase in sleep apnea 
CA enzymes are, as previously mentioned, widely expressed in the human body. With 
respect to relevance for ventilatory control and respiration, the CA enzymes are expressed in 
the lung, kidney, and red blood cells as well as in CNS regions corresponding to the central 
and peripheral chemosensors273. The occurrence of repeated apneas/hyponeas during sleep 
exposes the patient to cycles of hypoxia/hyperoxia and hypo/hypercapnia. In that sense OSA 
may resemble other situations with relative hypoxia including strenuous physical activity, 
chronic hypoxia or complex hyperventilation states that are known to alter the CA activity274-
276. Previous studies have also suggested that hypoxia influences the CA activity in human 
and chick embryonic development277-280. There are several mechanisms which could increase 
CA activity in the human body such as tissue hypoxemia as well as high altitude hypoxic 
exposure279,281. Moreover, an increased expression and activity of the CA enzyme may occur 
due to oxidative metabolism or reduced oxygen tension occurring at the molecular level274, 
282. 
The ventilatory effects of CA inhibition have been extensively studied in the past. 
Pharmacological agents with CA inhibitory properties (e.g. AZT) have been used for various 
respiratory conditions or diseases such as respiratory failure, high altitude periodic breathing 
and central apnea of type CSR as well as in OSA282-286. In fact, small controlled studies have 
Davoud Eskandari 
22 
reported that pharmacological CA inhibition reduces AHI with30 to 50% and improves 
nocturnal oxygenation in patients with OSA49,282,283,287. Furthermore, RCTs have reported a 
suppression of both obstructive and central breathing events by CA inhibition in OSA 
patients traveling to high-altitude288,289. An improvement on SDB and SDB related symptoms 
(e.g. EDS) in response to treatment with AZT has also been reported in patients with CSA, 
more specifically in heart failure patients with CSR290,291. CA inhibitors have commonly been 
proposed as prophylaxis in healthy subjects in situations where periodic breathing may 
develop, such as acute-mountain sickness292,293.  
 
Figure 8. Overview the principle mechanism behind increased ventilation by carbonic anhydrase 
inhibition 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The most important mechanism by which CA inhibition can promote ventilation is 
considered to be via the renal system (Figure 8)263. Inhibition of CA in proximal and distal 
tubules of the renal system generates a loss of bicarbonate in urine with metabolic acidosis 
as consequence and this will further promote ventilation via chemosensory mechanism294. 
The response of the induced respiratory alkalosis is to reduce PCO2 and hydrogen ion (raising 
pH) concentration by an increase in ventilation295. In addition, the stimulatory effects of CA 
inhibition on ventilation may also be attributed to the inhibition of the enzyme in red blood 
cells and vascular endothelium285,296,297. CA inhibition increases tissue CO2 retention in the 
vicinity of peripheral and central chemoreceptors which, in addition to the metabolic 
acidosis, will provide a further stimulus to ventilate. CA inhibition reduces the rate of 
response to CO2 while increasing the hypoxic ventilatory response
273,298. More recent studies 
have shown that CA inhibitors (e.g. AZT) improve ventilatory stability by reducing LG in CRS 
and OSA patients49,290. In addition, as reported by Edwards et al. AZT reduces the ventilatory 
overshoot in response to an arousal, an effect which further improves the ventilatory 
stability in selected OSA patients299. 
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Carbonic anhydrase and cardiovascular function/disease 
In addition to effects on respiration, CA enzymes appear to be expressed in various tissues 
where their activity may relate to CV regulation (e.g. HT, Table 2).  Most of the insights in 
this area have been obtained in experiments using inhibition of the CA system. It is possible 
that the hemodynamic effects induced by CA inhibitors in some cases may involve 
mechanisms unrelated to CA300. However, in the context of OSA with comorbid vascular 
disease such as HT it may be speculated that a possible dual effect on respiration and 
hemodynamic control would be of particular value.  
As shown in Table 2, CA is present in vascular endothelium, a tissue which is known to 
produce multiple substances (e.g. nitric oxide, endothelin 1) directly implied in the 
regulation of vascular tone301-303. The enzyme is also present in vascular smooth muscle, 
blood lines (red, white and platelets) and in the heart (low concentrations)304-306. The 
expression of CA enzymes in these tissues is likely to contribute to regulation of physiological 
processes that include vascular resistance, cardiac contractility, diuresis and fluid shift307-310. 
In addition, with regard to CV regulation, the CA enzyme is expressed in central nervous 
system around peripheral and central chemoreceptors273,311,312. Indeed, there are numerous 
sites and pathways by which CA inhibition can affect the CV regulation in OSA patients.  
Table 2. Location and expression levels for different CA isoenzymes in the cardiovascular system  (adapted 
from Swenson, 2014
300
) 
 
 
 
 
 
 
 
 
 
 
 
Experimental studies have shown that CA inhibition contributes to vasodilation via direct or 
indirect mechanisms. In a forearm flow model CA inhibition modulated a calcium-activated 
potassium channel (decreasing cytosolic Ca2+ concentration) and induced vasodilation307. 
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Moreover, CA inhibitors, in very high concentrations, may block voltage gated calcium 
channels and thereby alter the vascular tone313. Experimental in-vivo and in-vitro studies 
have shown that the hypotensive effect of calcium-channel blocker to an extent is associated 
with their ability to inhibit CA in the vascular smooth muscles and erythrocytes314, 315. CA 
inhibitors may also induce vasodilation by modulation of nitric oxide metabolism in the 
vascular endothelium316,317. Other mechanisms by which CA inhibition may cause 
vasodilation include their ability to reduce the CO2 carrying capacity of red blood cells. The 
increase of tissue pCO2 will cause hypercapnia with a subsequent vasodilatory response to 
reduce CO2 levels
318,319. 
 
Several physiologic effects of CA inhibition are more apparent during hypoxic conditions (e.g. 
high-altitude). Experimental studies on hypoxia exposed animals showed a decrease of 
pulmonary vascular resistance and vasoconstriction following treatment with AZT320,321. The 
effects of AZT on hypoxic pulmonary vasoconstriction were also demonstrated in RCT´s that 
included healthy subjects traveling to high-altitude286,322. However, this effect may not have 
been related to CA inhibition323,324. An effect on systemic HT was demonstrated by Parati et 
al. who reported that elevated brachial BP following acute exposure to high-altitude and 
hypobaric hypoxia in healthy volunteers was counteracted by AZT325. A similar effect, linked 
to reduction of nocturnal transcutaneous PCO2, was reported in OSA patients traveling to 
high- altitude289. 
It should be noted that several conventional CA inhibitors (e.g. AZT or ZNS), not accounting 
for thiazides and loop diuretics, act as diuretics and have shown to reduce extracellular fluid 
volume (5-10%)326. In the context of the current thesis it is also plausible that diuretic effect 
related to CA inhibition potentially may account for BP lowering effects. However, studies 
have shown that CA inhibition by AZT has not resulted in any significant BP reductions in 
normal subjects with essential HT327,328.  
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6 Aims of the thesis 
The overall aim of this project was to investigate the association between obstructive sleep 
apnea (OSA) and activity of the carbonic anhydrase (CA) system. In addition, we aimed to 
explore the influence of CA inhibition on blood pressure (BP) control and sleep apnea 
severity in OSA patients. The thesis is based on the following studies; 
1. Paper I 
Aimed to establish an association between arterial standard StHCO3
-, as a 
proxy for CA activity, OSA severity as well as hypertension. 
 
2. Paper II 
Explored the association between the whole blood CA enzyme activity and 
OSA severity. In addition, the association of CA activity and blood pressure 
(BP) was investigated.   
 
3. Paper III 
Investigated the therapeutic effects of a pharmacological CA inhibitor, 
zonisamide, on SDB in overweight/obese OSA patients.  
 
4. Paper IV 
Explored the combined therapeutically effectiveness of AZT (CA inhibitor) in 
direct comparison with CPAP therapy on sleep disordered breathing and 
blood pressure/vascular function in patients with OSA. 
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7 Methods 
7.1 Study population and design 
Four different groups of patients were studied in this thesis. All four study populations in 
paper I through IV had been referred for investigation of suspected SDB.  The study 
populations were predominantly middle-aged males. Obesity was common as was HT and 
sleepiness. The population in paper IV was selected based on an existing HT diagnosis.  
Table 3. Baseline characteristics of patients in Papers I through IV.  
 Paper I Paper II Paper III Paper IV 
Cohort OSA patients OSA patients OSA patients OSA patients 
Population, n 830 70 42 13 
Age (yrs) 51 (10) 54 (13) 51 (12) 64 (7) 
Gender(% Males) 93 69 93 100 
BMI (kg/m2) 30 (5) 30 (6) 31 (2) 29 (4) 
SBP (mmHg) 146 (20) 138 (20) 135 (17) 157 (11) 
DBP (mmHg) 94 (13) 84 (11) 84 (9) 86 (11) 
HR (bpm) 73 (11) 69 (11) 59 (8) 62 (9) 
AHI (n/hr) 32 (24) 27 (23) 47 (24) 37 (22) 
ESS - 11 (5) 13 (4) 9 (4) 
HT prevalence (%) 53 46 32 100* 
*= Population based on hypertensive OSA patients. 
 
7.2 Study design and procedure 
Epidemiological sleep clinic cohort (Paper I) 
Paper I was based on a retrospective population cohort containing patient referrals (n=1665) 
to the Marburg Sleep Disorders Centre (between the years 1989 and 1992)329. An AHI cut-off 
of ≥5 events/hr was implemented for inclusion. Exclusion criteria included respiratory failure 
(n=163), obesity hypoventilation syndrome (OHS) (n=38) and COPD (n=163). An additional 
363 patients were excluded due to missing data (arterial blood gases, pulmonary function, 
and BP).  A total of 830 patients met the above mentioned criteria and were included in the 
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final data analysis which investigated the association between arterial standard bicarbonate 
(StHCO3
-), apnea severity and HT. 
Experimental study (Paper II) 
Patients (n=74) included in this experimental study were randomly recruited among those 
referred for suspected OSA to the Department of Sleep Medicine at the Sahlgrenska 
University Hospital. Exclusion criteria included an established history of COPD or OHS (n=4). 
The final analysis was made on data from 70 patients that underwent a full night 
cardiorespiratory polygraphy recording at the sleep clinic. Blood samples for assessment of 
CA-activity, office BP and HR were collected and recorded in the morning immediately 
following to the sleep recording. 
Interventional studies (Paper III and IV) 
The papers III and IV included patients with a recognized diagnosis of OSA and considered 
for therapy with CPAP. The patients were recruited at the Department of Sleep Medicine, 
Sahlgrenska University Hospital. The detailed inclusion and exclusion criteria applied in these 
studies are given in Table 4.  
Table 4. Inclusion and exclusion criteria for interventional studies paper III and IV. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Davoud Eskandari 
28 
Paper III was based on an interventional study using randomized, placebo-controlled, 
double-blind, and parallel group design. In addition to a placebo-controlled phase (a total of 
4 weeks), the study also contained an open-label phase (5 months) that compared the effect 
of ZNS and CPAP on SDB. A total of 50 patients were screened and subsequently randomized 
(n=47) to ZNS (n=16), placebo (n=16) or CPAP treatment (n=15). Three patients withdrew 
consent prior to randomization. Following the short-term treatment phase, study subjects 
from the placebo group were allocated to ZNS treatment. Assessments of SDB, office BP, 
blood samples and biochemistry, anthropometrics, questionnaire data were conducted at 
baseline, 4 weeks and 24 weeks. Baseline PSG included a habituation night.  
Paper IV was based on a single center, open (blinded for data analysis), randomized three-
way cross over trial. Details of the study design are given in Figure 9. A total of 22 male 
patients were identified as eligible but only 14 met all inclusion/exclusion criteria. All 
ongoing antihypertensive treatment was washed-out prior to randomization. One patient 
was excluded during withdrawal of antihypertensive medication due to high BP. The 
remaining 13 patients were randomized to receive AZT, CPAP or the combination of the two 
(n=12). The subsequent allocation to the treatment modalities followed a blinded 
randomization code administered by personnel not involved in the study. Each of the six 
study visits applied an ambulatory PG recording during sleep as well as assessment of office 
BP, blood samples and biochemistry, anthropometrics and a program of daytime functional 
hemodynamic tests performed in conjunction to the sleep recording. Treatment periods 
were separated by a two weeks wash-out period. 
Figure 9. Overview of study flow chart for Paper IV 
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7.3 Ethical considerations 
Paper I was approved by the Ethics committee at Marburg University, Marburg, Germany. 
Protocols for papers II-VI were approved by the Ethics committee at University of 
Gothenburg. Written and oral informed consent was obtained from all participants prior to 
the study entry. Paper III and IV were registered on online clinical registries sites 
clinicaltrials.gov and European Clinical Trials Database (EudraCT). 
7.4 Anthropometric, clinical and questionnaire data 
Anthropometric and clinical data were collected throughout all studies. Bodyweight and 
height were determined to the nearest 0.1 kilograms and centimetres, respectively.  BMI 
(kg/m2) was calculated as bodyweight (kilograms) divided by the height squared (meters). 
Sagittal diameter, waist circumference and hip girth, all expressed in centimetres, were 
assessed in Paper III.   
Information regarding comorbidities (e.g. DM and CV disease), concomitant medication, 
smoking and alcohol consumption was based on self-reported information or a physician´s 
diagnosis and recorded and documented for all subjects. Potential suicidal risk or behaviour 
as well as anxiety (Papers III and IV) were assessed by relevant validated questionnaires 
including the Columbia suicide severity rating scale and the Zung self-rated Depression and 
Anxiety scales330-332. The Clinical Global Impression scale, severity and improvement scales, 
was used to determine symptom severity, treatment responses and efficacy. Side effects and 
safety were monitored prior to study start and monitored throughout the entire study 
period(s). The Epworth sleepiness scale (ESS, Paper II-IV), the Functional Outcomes of Sleep 
Questionnaire and the Fatigue impact scale (Paper III) were used to determine subjective 
EDS as well as sleep and fatigue-related effects on quality of life98,99,333.  
7.5 Biochemistry assessment 
In paper I, arterial blood gases were obtained at 12 a.m. following the sleep assessment and 
analysed using a Radiometer gas analyser (Radiometer, Copenhagen, Denmark). 
Biochemistry and venous blood sample data in Paper II-IV were collected in the morning 
subsequent to the sleep recording visits. All assessments were conducted during fasting 
conditions. Samples were analysed according to clinical routine procedures at the 
Department of Clinical Chemistry, Sahlgrenska University Hospital, Gothenburg. 
7.6 Blood pressure, heart rate and hemodynamic assessment 
Office BP and HR measurements were assessed according to international standard334-336. 
Systolic/diastolic BP (SBP/DBP) and HR were determined with the patient in a sitting position 
following a minimum of 10 minutes rest and expressed as the mean of two subsequent 
recordings in Paper I. In paper II-IV BP and HR were assessed with an automated Omron M6 
recorder (Omron Healthcare, Kyoto, Japan). Office SBP/DBP and HR in paper II-III and IV 
were expressed as the mean of two or three subsequent recordings (1 minute intervals) in 
the supine position after a 10-minute rest, respectively. Office BP was expressed in mmHg 
and HR in terms of mean beats per minute (bpm).  Mean arterial pressure (MAP) was 
calculated according to the formula MAP= (1/3*SBP) + (2/3*DBP).  
Davoud Eskandari 
30 
Definition of hypertension (paper I) 
Patients with a previous history of clinically diagnosed HT and/or on ongoing hypertensive 
medication were defined as hypertensives. In addition, patients with no previous 
hypertensive medical history and/or no ongoing anti-hypertensive treatment were defined 
as normotensives. 
Non-invasive Arteriography (Paper IV) 
Arterial stiffness and central hemodynamic parameters were determined by a validated 
oscillometric method using a sensor placed at the skin surface over the radial artery 
(Arteriograph, TensioMed®, Hungary, version 1.10.1.11)337,338. Arterial stiffness and central 
hemodynamic parameters included aortic and brachial augmentation index, central aortic 
SBP/DBP and pulse pressure. All non-invasive arteriography recordings were measured 
during fasting conditions between 8-10 a.m. and conducted in a semi-recumbent position 
following a minimum of 10 minutes rest in the supine position. All data were automatically 
analyzed according to the built-in device algorithm.  
7.7 Sleep studies  
Polygraphic recordings 
Paper I 
The ambulatory PG recordings in paper 1 were performed using the MESAM 4 polygraphy 
device (MAP, Munich, Germany). This device has been validated for assessment of SDB in 
clinical and epidemiological studies339,340. The PG montage included finger pulse oximetry, an 
electrical-miniature microphone placed over the larynx to assess snoring, ECG, and a circular 
sensor below the sternum to assess body position. Apnoic and hypopneic events were 
visually determined using a ≥4% oxygen desaturation criterion. A more detailed description 
of the scoring procedure has previously been described elsewhere340. Information derived 
from sleep diaries (lights on/off, periods of sleep interruption, time of going to 
bed/awakening) was used to estimate sleep time. The AHI was defined as the number of 
total apneas and hypopneas divided by sleep time.   
Paper II and IV 
Ambulatory (Paper IV) or sleep laboratory attended (Paper II) cardiorespiratory PG recording 
were conducted using the Embletta® X10 Portable Digital System device (Embla, CO, USA). 
The recording montage consisted of a nasal cannula, thorax/abdominal respiratory effort 
belts by means of inductive plethysmography, and finger pulse oximetry. Apnea events were 
defined as a cessation of airflow (≥90%). Hypopnea events were defined as a decrease of 
airflow (≥ 30%) associated with a ≥ 3% or 4% (paper II) oxygen desaturation. For an event 
classification duration of at least 10 sec was required. Apnea-hypopnea index (AHI) was 
calculated as the total number of apnea/hypopnea events divided by analysis time (lights 
off/lights on period during recording session). The ODI was calculated as the total number of 
≥4% desaturations divided by analysis time. Mean nocturnal oxygen saturation (SpO2) was 
calculated as the mean oxygen saturation measured by finger pulse oximetry during analysis 
time. Data was scored and analyzed according to the 2007 AASM criteria102. OSA severity 
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(Paper I and II) was defined according to a grading scale as mild (5≤AHI<15 n/h), moderate 
(15≤AHI<30 n/h) or severe (AHI≥30 n/h). 
Ambulatory PSG (Paper III) 
All study participants underwent ambulatory polysomnography (PSG) studies using the 
Embla A10 system (Embla, Flaga, Reykjavik, Iceland). The ambulatory PSG recording montage 
(Paper III) included electroencephalograms (C3-A2, C4-A1, FZ-A2, OZ-A1), 2-channel 
electrooculograms, submental (chin) and bilateral tibialis electromyograms and 2-channel 
electrocardiogram. In addition, information from a nasal cannula and an oro-nasal 
thermistor, thoracic and abdominal respiratory effort belts, body position sensor and finger 
pulse oximetry was used for the assessment of SDB. The AHI was calculated as the total 
number of apneas/hypopneas divided by total sleep time. Apneic events were defined as an 
almost complete cessation (≥90%) of the airflow persisting at least ≥10 seconds. Hypopneic 
events were defined as a decrease in airflow signal (≥50%) persisting ≥10 seconds and 
associated with a ≥3% decrease in oxygen desaturation or an arousal. The ODI was 
calculated as the total number of ≥4% desaturation divided by total sleep time. Furthermore, 
the mean, minimum and time spent below 90% oxygen saturation were recorded. All data 
were analyzed and scored according to the 2007 AASM criteria by an experienced and 
blinded (for treatment allocation) PSG technician. Study participants underwent two full 
consecutive PSG nights at baseline102. Data from the first PSG was considered as obtained 
from a habituation night and was not included in the analysis.  
Subjective sleep time 
In paper III, subjective sleep time (habitual sleep time) for assessment of the overall CPAP 
treatment effect (concept of OSA alleviation was assessed by sleep diaries initiated two 
weeks prior to each PSG-visit12. The habitual sleep time was calculated as the mean of all 
subjectively reported sleep time in the CPAP and ZNS groups at 24 weeks. Habitual sleep 
time in Paper IV was calculated as the mean of the lights-off to lights-on times assessed by 
PG in accordance with each study visit (a total of six visits). 
7.8 CPAP initiation, compliance and adherence (Paper III and IV) 
CPAP treatment was conducted by standard auto adjusting positive airway pressure devices 
(S8 Autoset Spirit II or S9 Autoset, ResMed Ltd, Sydney, Australia). CPAP pressure range was 
set to vary between a minimum of 5 and a maximum of 15 cmH2O. CPAP introduction and 
training was conducted according to standard hospital clinical routines. Mask pressure, 
leakage, usage hours (mean/total) and residual AHI were documented by the built-in device 
memory cards at each follow-up visit. Patients were encouraged to contact the study 
personal between the scheduled visits if any problem with the device occurred. Data was 
acquired and analysed by ResScan™ software (version 3.14, ResMed Ltd, Sydney, Australia).  
7.9 Study drug , titration and  compliance  
Paper III 
ZNS (100mg, Zonegran®, Eisai Ltd, UK) or placebo tablets were titrated in a stepwise manner 
starting with a daily dosage of 100 mg and an option to escalate dosing on a weekly basis to 
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reach a maximum daily administered dosage of 300 mg. Recommended time for intake of 
medication was set at 8-10 pm corresponding to 1-2 hours prior to sleep. Compliance and 
mean daily dosage with the study drug and placebo were determined and calculated by 
tablet count. In the event of a side-effect the daily dosage could be reduced (100 mg steps). 
The total duration of the drug treatment was 20 weeks or 24 weeks pending on the 
randomisation schedule. 
Paper IV 
AZT (250mg, Diamox®, Mercury Pharmaceuticals Ltd, London, UK) was administered 
according to incremental dosing steps starting at 250mg/day and set to reach a maximum 
dosage of 750mg/day. Recommended medication intake was at two hours prior to bedtime.  
Compliance and mean daily dosage with the study drug and placebo was determined and 
calculated by tablet count.  The total duration of drug treatment was 2x2 weeks. In the event 
of a side-effect the daily dosage could be reduced (250 mg steps) 
7.10 Therapy compliance adjustment (Paper III and IV) 
SDB (e.g. AHI and ODI) was adjusted for CPAP and drug compliance in order to compare 
therapeutic efficacy of the two treatment modalities. Drug compliance (%) was calculated as 
actual total dosage/day divided by maximum daily dosage, as determined by tablet count. 
Furthermore, the obtained value was multiplied with treatment effect, e.g. absolute change 
in AHI/ODI (%). CPAP efficacy was adjusted and corrected for therapy (hrs/night) and 
habitual subjective sleep length (hrs/night corresponding to overall apnea exposure) in order 
to reflect the proportional sleep time with CPAP use (%). 
Sleep apnea alleviation (SAA%, paper III) was computed and expressed as the therapeutic 
effect of CPAP after adjustment for absolute user time, relative efficacy of the therapy 
(corrected AHI or residual AHI) and the mean habitual sleep time. SAA% enables a 
comparison between mechanical and pharmacological treatment that adjusts for the 
incomplete compliance with CPAP. The details of the SAA% assessment has previously been 
described elsewhere12, 287. In brief, compliance data from the built-in CPAP meter was 
adjusted for subjective habitual sleep time. Furthermore, the CPAP treatment effects on 
AHI/ODI relative to the baseline were calculated. SAA% was expressed as the multiplied 
percentage of efficacy and actual user time of CPAP. 
7.11 Assessment of carbonic anhydrase activity (Paper II) 
The method used to determine CA activity from blood samples has previously been 
described341,342. CA enzyme activity assessments were conducted by repeated 
measurements and duplicate samples in the analysis in order adjust for possible inter- and 
intra-assay variability. A pH meter (Docu-pH+, Sartorius, Sweden) was used to continuously 
monitor pH. Venous blood samples were obtained and stored at -70 oC. A procedure of 
thawing, re-freezing and thawing was performed for hemolysation of the sample. A buffer 
(pH range 6-8) comprised of MES (2-(N-morpholino) ethanesulfonic acid), HEPES (4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid), sodium chloride and potassium chloride was 
prepared. All subsequent analyses were performed on ice in order to maintain temperatures 
between 0-1 oC. A separate solution consisting of distilled water was continuously flushed 
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with CO2 (100%) for a minimum of 30 min. The venous blood sample (diluted (1:2000) in 
0.9% saline) was added to the buffer solution in a reaction vessel with continuously 
monitored pH (see Figure 10). After a baseline pH (8.00 ±0.03) had been established, the CO2 
saturated solution was added into the reaction vessel (Figure 10). 
The pH was monitored during 120 seconds. Self-developed software was used for plotting 
and analyzing the pH curves. Area under the curve (AUC, range 802-837) was calculated and 
defined as the sum of pH assessments during the recording interval and assumed to 
correspond to the venous blood CA-activity (Figure 10). The CA-activity was defined as AUC 
(arbitrary units). Thus, a lower calculated AUC corresponds to higher CA-activity (i.e. a 
shorter reaction time). 
Figure 10. Overview of the methodological procedure for the assessment of carbonic anhydrase 
activity and the catalyzed reaction by addition of carbon dioxide to the reaction vessel 
 
 
 
 
 
 
 
 
 
7.12 Statistics 
The statistical analysis in papers I-IV was conducted using IBM SPSS 19, 20 and 22 (SPSS Inc, 
Chicago, USA). A two-tailed p-value of <0.05 was considered as statistically significant.  Data 
are presented as mean (standard deviation, (SD)), median and interquartile range (IQR, 25% 
to 75%), and mean change and 95% confidence interval (CI). The normality and distribution 
of data were determined by Kolmogorov-Smirnov test or Shapiro–Wilk t-test. Kruskal-Wallis 
test and one way analysis of variance (ANOVA) was used to determine across group 
differences. Data in the interventional studies (paper III and IV) were analysed as per-
protocol. The arterial StHCO3
- as well as the AHI and ODI were logarithmized in paper I and II, 
respectively, in order to receive normally distributed data.   
Paper I 
Associations between arterial StHCO3
-, AHI, SBP and DBP were studied by Spearman 
correlation. Group differences between different StHCO3
- quartiles were assessed by 
independent sample t-test. Independent association between arterial StHCO3
-, AHI, 
CO2 
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hypertensive status as well as office BP were studied using multivariate generalized linear 
models.  
Paper II 
Group comparisons were assessed by Mann-Whitney U-test. The association between CA 
activity, OSA and BP were addressed using Pearson and Spearman correlations. Independent 
associations between CA-activity, OSA severity and BP were assessed by generalized linear 
models, with logAHI/ logODI, and sitting diastolic BP respectively, as the dependent 
variables. 
Paper III  
Within group differences with regards to sleep-related, anthropometric and biochemistry 
variables at week 4 and 24 were studied by paired sample t-test. Comparison between 
treatment modalities was assessed by analysis of covariance (ANCOVA). 
Paper IV 
ANOVA or Kruskal-Wallis was used to compare and assess between group differences at 
baseline. Within group comparisons were computed by Paired sample t-test and Wilcoxon 
signed-rank.  Associations between venous StHCO3
-, respiratory and BP variables were 
assessed by Pearson and Spearman correlations. Between groups comparisons were studied 
by independent sample t-test or Mann-Whitney.  
Sample size estimation 
In paper III, the study sample size was determined based on data from in-house 
pharmacological studies in OSA patients. We assumed that the pharmacological treatment 
would reduce AHI by ≥7.5 (6.0) events per hour compared to placebo. A parallel group 
design with 30 patients on each treatment arm would have a power exceeding 90% for 
detecting a treatment group difference in primary efficacy variable(s) (using a two-sample t-
test with a 5% significance level). 
In paper IV, the sample size was determined based on data similar studies that had 
examined the effect of CPAP or a CA-inhibitory drug on MAP287. In detail, a cross-over design 
study would need 30 patients, based on that a reduction of MAP after AZT treatment would 
exceed that of CPAP by 5 (10) mmHg and a to obtain a power of 80% for detecting a 
treatment group difference (two tailed t-test with a 5% significance level). 
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8 Main Results and discussion 
8.1 Association between CA-activity and OSA  
Paper I 
This study included 830 predominantly middle-aged overweight-obese males undergoing a 
diagnostic sleep study (93.3% men, age 51(10) years, BMI 30(5) kg/m2, AHI 32(24) n/h,   
Table 3). Arterial blood gases had been performed in all patents and standard HCO3
-  
(StHCO3
-) was found to increase gradually across OSA severity classes although the 
magnitude of the mean change was moderate (ANOVA, p<0.001). AHI in the lowest quartile 
was 27(21) and in the highest quartile 39(26) suggesting that considerable SA was present in 
all quartiles. StHCO3
- was positively correlated with AHI (Spearman correlation r=0.16, 
p<0.001) and StHCO3
- was independently associated with AHI (Q1 vs. Q4 β=10.6, p<0.001) in 
a generalized linear model controlling for sex, age, BMI, smoking, alcohol consumption, pO2, 
pCO2 and HT status.  
StHCO3
- was approximately almost one mmol/l higher in hypertensive (24.9±2.7) compared 
with normotensive (24.1±1.9) patients (p>000.1). Moreover, the association between OSA in 
the highest severity class (AHI≥30) and StHCO3
- was observed only in hypertensive OSA (and 
not normotensive) (p<0.007 and p<0.001 compared with the moderate (AHI 15-29.9) and 
mild (AHI 5-14.9), respectively. StHCO3
- expressed as logStHCO3
- was independently 
associated with a clinical diagnosis of HT in a generalized linear model controlling for sex, 
age, BMI, smoking, alcohol, PO2, PCO2 and apnea severity (Q1 vs. Q4 β=8.o, SE 3.0, 95%CI 
(2.1-13.8, p=0.007). The association between AHI and BP appeared to be stronger for 
diastolic than SBP.  
Paper II 
Baseline characteristics of 70 patients participating in this study are shown in Table 3. The CA 
activity in patients without OSA, (AHI<5), mild (5≤AHI<15), moderate (15≤AHI<30) or severe 
(AHI≥30) OSA was 23.7(5.5), 25.2(8.3), 27.3(6.0) and 33.9(8.5) units, respectively (Kruskal-
Wallis test, p=0.001). CA activity increased in a dose-response manner along with 4% oxygen 
desaturation index (ODI4) quartiles (Kruskal-Wallis test, p<0.001, Figure 11) and peaked in 
the two upper compared with the lowest quartile (Mann-Whitney test, for Q3 p=0.001 and 
for Q4 p<0.001). There was a positive correlation between CA activity and AHI as well as 
ODI4 (Spearman correlation, r=0.44 and 0.47, respectively, both p<0.001). Mean nocturnal 
SpO2 was negatively associated with CA activity (Pearson correlation, r
2= 0.091, p=0.011). In 
two separate generalized linear models controlling for age, sex, BMI, pre-sleep oxygen 
saturation, mean nocturnal SpO2, HT status and use of diuretic medication, CA activity was 
found to be significantly associated with logAHI and logODI4 (β=0.020 and 0.017, p=0.007 
and p=0.011, respectively). This association remained significant after controlling for 
haemoglobin concentration. 
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Figure 11. CA activity in relation to quartiles of 4% oxygen desaturation index 
 
 
 
 
 
 
 
Discussion and implications (papers I and II) 
All patients in these studies were those investigated for SA in a routine sleep clinic setting. 
Hence, the recruitment is heavily skewed against subjects with established OSA and the 
contribution of healthy subjects is low. Moreover, the prevalence of comorbid medical 
conditions that may influence the results is high59. These limitations would tend to decrease 
the possibility to discriminate patterns of SDB or HT in relation to a tentative biomarker such 
as StHCO3
-. Indeed, the distribution of StHCO3
- was also wide at any given AHI severity.  
The HCO3
- concentration in the body is regulated by multiple mechanisms, including renal 
excretion, which are likely to attenuate potential respiration (or OSA) induced changes in 
StHCO3
-263. Moreover, StHCO3
- in the arterial blood stream may not be fully representative 
for the state of the acid-base balance in various compartments of the body. Particularly not 
those involved in chemosensory control of respiration. In our material StHCO3
- ranged from 
22.0 in the lowest AHI quartile to 27.2 in the highest. Although this difference across severity 
groups was proportionally low it remains that StHCO3
- may reflect a clinically relevant 
difference in CA activity.  
Further, it is important to recognize that StHCO3
- may be regarded as a surrogate marker for 
CA activity in the body. As such, assayed StHCO3
- might stem from multiple sources provided 
by various CA isoenzymes for instance in the lung, capillary epithelium, and kidney or 
muscle262,273. In paper II we attempted to directly assess CA activity in whole venous blood 
by means of a newly developed ex-vivo technique based on pH conversion speed. In 
consideration of the described localization of various CA isoenzymes it is likely that we in this 
model predominantly assess activity of CA I and II which represent the prevailing isoforms in 
the erythrocyte membrane or cytoplasm262. Much like the situation for StHCO3
- in the 
previous experiments the activity was increased across the AHI severity range. Moreover, in 
this experiment, which also assessed various measures of oxygen saturation in particular 
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nocturnal saturation, and hypoxemia, there was a similar severity related increase of CA 
activity. While the first cohort study used an early and less advanced diagnostic technique 
without assessment of oxygenation339,340, a more conventional technique was applied in the 
second study. It is possible that relative inaccuracy in the sleep recording may have 
contributed to the relatively high variation in the scatter plots depicting the correlation 
between the AHI and the 4%ODI and CA activity. CA activity is conventionally linked to CO2 
elimination rather than hypoxemia and a potential mechanistic link between hypoxia and CA 
activity in the context to OSA remains to be clarified. However, animal experiments have 
suggested a role of CA in regulating the ventilatory responses to both O2 and CO2 in the 
carotid body343-345. It is also likely that respiratory events during sleep will lead to local tissue 
acidification and CO2 retention in a manner that triggers an elevated activity of CA in several 
tissues277,278 346. In addition, other factors such as the ventilatory stability may be affected by 
local CA activity. The “loop gain”, which may be regarded to reflect the ventilatory response 
to CO2, determines ventilator stability and this integrity may be increased by 
pharmacological inhibition of the CA system43, 44,49 .  
When summarizing the two studies dealing with markers of CA activity in patients with OSA 
there appears to be an elevation of CA activity (or the surrogate biomarker StHCO3
-) in 
subjects with more severe OSA. The causality of this association remains unknown but may 
be addressed by experiments that either assesses the CA activity before and after 
elimination of OSA or the effect of pharmacological inhibition of CA on the intensity of OSA. 
The current experiments do not provide solid support for a potential role of CA activity 
monitoring as a potential biomarker in OSA. However, there is a possibility that elevated CA 
activity in association with OSA represents a unique phenotype of the disorder. Candidate 
characteristics of such a phenotype may be speculated to include either high loop-gain or 
unstable breathing of elevated likelihood of HT development. 
8.2 Influence of CA inhibition on OSA 
Paper III 
The CA inhibitor ZNS (n=13) was compared to placebo (n=15) in a randomized, controlled 4 
week study addressing SDB and electrophysiological assessed sleep. The two study groups 
did not differ at baseline, expect for a marginally bigger waist to hip ratio in the ZNS group.  
Patients were middle aged, obese and had severe OSA (age 54(12) yrs, BMI 31(2) kg/m2, AHI 
46(23) n/hr and ESS 12(4), respectively). ZNS, compared to placebo, induced a potent 
reduction of both AHI and ODI (Table 5). The reduction of AHI in the ZNS group was primarily 
due to alleviation of hypopneas (-5.7 [-10.8 to 0.4], p=0.07). Furthermore, group 
comparisons showed significant improvements in the mean SpO2 and the arousal index that 
favoured ZNS (p=0.04 and 0.02, respectively). BMI was marginally reduced by ZNS but the 
size of the weight reduction was unrelated to the change of the AHI or ODI. Furthermore, 
ZNS potently reduced the venous StHCO3
- concentration, but this change did not correlate 
with the improvement in AHI or ODI. No improvements were recorded for either EDS or 
fatigue. 
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Table 5. Baseline values and effects of 4 weeks treatment of placebo or ZNS on sleep-related variables 
 
 
 
 
 
 
 
 
 
 
 
CPAP (n=11) treatment was superior to ZNS (n=22) with regard to OSA reduction as well as 
improvement of OSA-related outcomes such as EDS and fatigue at 24 weeks. Study drug 
compliance was 96.4 (8.7) % at 24 weeks while the averaged CPAP usage over 24 weeks was 
5.2 (1.4) hours/night. The significant difference in AHI/ODI reduction was maintained also 
after adjustment of CPAP and drug compliance (computation of a SAA%, Table 6). CPAP 
treatment did not induce any changes in StHCO3
-. Secondary outcomes including nocturnal 
oxygenation were improved by ZNS but ZNS induced increased apnea duration at the 24 
week assessment. Body composition, including neck circumference, BMI and sagittal 
diameter was significantly reduced by ZNS compared with CPAP but this change was not 
correlated with the reduction of AHI or ODI in the ZNS group. The effect on StHCO3
- induced 
by ZNS was maintained at 24 weeks but remained unrelated to the change in AHI and ODI 
(Spearman correlation=-0.02 and 0.17, p=0.94 and 0.45, respectively). 
 
 
 
 
 
 
 
Abbreviations: AHI= apnea hypopnea index; ODI=oxygen desaturation index; ESS= Epworth sleepiness 
scale; BMI= body mass index; HCO3-= venous standard bicarbonate 
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Table 6. Baseline values and effects of 24 weeks treatment of CPAP or ZNS on sleep-related variables 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Paper IV 
This was an open, randomized, cross-over study comparing respiratory and hemodynamic 
effects of AZT, CPAP and AZT/CPAP in thirteen male OSA subjects (age 64 (7) years, BMI 29 
(4) kg/m2, AHI 37 (23) n/hr). The analyzed groups did not differ at baseline with respect to 
anthropometrics, SDB or BP. Mean study drug compliance was 94.6 (7.1)% and 94.5 (7.6)% in 
the AZT and AZT/CPAP group, respectively. Mean CPAP usage was 4.8 (2.2) and 5.0 (2.0) 
hrs/night for the CPAP and AZT/CPAP groups and habitual sleep time was 7.3 (1.2) hr/night. 
The main findings from paper IV are summarized in Table 7. 
CPAP, AZT and AZT/CPAP all significantly reduced AHI and ODI (all p<0.005, Table 7). The 
reduction of the AHI and ODI corresponded to 42 (27) and 46 (25) %, respectively, compared 
with baseline in the AZT group. The change was mainly due to elimination of apneic events (-
10.3 [-17.6 to -2.9] n/hr, data not shown). Measures of oxygenation including mean 
overnight and minimum SpO2 were increased after AZT. However, the hypopnea duration 
was increased after AZT (7.2 [1.9 to 12.5] sec, p=0.01). The resolution of respiratory events 
was more pronounced after CPAP and AZT/CPAP than after AZT (all p<0.05, Table 7). CPAP 
and AZT/CPAP improved minimum SpO2 more effectively than AZT but only AZT/CPAP 
treatment improved mean SpO2 compared to AZT therapy (p<0.01). The differences between 
Abbreviations: AHI= apnea hypopnea index; ODI=oxygen desaturation index; ESS= epworth sleepiness 
scale; BMI= body mass index; HCO3-= venous standard bicarbonate 
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therapeutic modalities in terms of AHI or ODI did not remain significant if an adjustment for 
CPAP and drug compliance was made (Figure 12).  
There were no recorded improvements in EDS as reflected by the ESS score in the treatment 
groups. BMI was reduced after AZT but the size of the change in BMI was not associated with 
the reduction in AHI or ODI (Spearman correlation, r2=0.24 and -0.17, p=0.42 and 0.61, 
respectively). Venous StHCO3
- was reduced in the AZT and AZT/CPAP groups and the degree 
of reduction of StHCO3
- concentration was linearly associated with the reduction of AHI 
(Spearman correlation, r2=0.66 p=0.013).  
Table 7. Treatment effects of CPAP, AZT or AZT/CPAP on sleep disordered breathing 
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Figure 12. Mean unadjusted and compliance adjusted reduction in apnea-hypopnea index (AHI) 
after treatment with CPAP or AZT 
 
 
 
 
 
 
 
 
 
The effect of CA inhibition in OSA was applied and studied by two different compounds, ZNS 
and AZT, in papers III and IV, respectively. In order to better evaluate the overall effect of CA 
inhibition in OSA we subsequently added the data obtained in these two studies. As a 
general observation AZT appeared to more potently modify OSA although the observed 
differences may not necessarily reflect pharmacological differences but rather the influence 
of study design, study durations, dosing or blinding procedures which differed between the 
two studies. Hence, data from this combined analysis, which is summarized in Table 8, needs 
to be interpreted with caution. This combined analysis suggested that respiratory related 
markers of OSA were potently reduced (in the order of 30%), along with StHCO3
- 
(approximately 20%) and the BMI (approximately one unit). In this combined analysis 16/26 
(69.6%) of patients treated with either ZNS or AZT could be labelled responders (≥20% 
reduction of AHI) and 8/26 (30.8%) reduced the AHI by at least 50%. The number of 
responders (≥20% reduction of AHI) in the respective AZT and ZNS treated groups were 
76.7% and 46.2%, respectively. The reduction in AHI was positively correlated with the 
change in StHCO3
- (Spearman correlation r2=0.44 and p=0.04, Figure 13) when both 
compounds were taken into account. However, the effects on AHI did not remain significant 
when BMI was included as a covariate in the univariate model.  
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Table 8. Estimated therapeutic effect of CA inhibition on OSA as reflected by two different substances (ZNS 
and AZT) in Paper III and IV 
 
 
 
 
 
 
 
 
 
 
Figure 13. Relationship between the change in AHI and the change HCO3
- 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: AHI= apnea hypopnea index; ODI=oxygen desaturation index; ESS= epworth sleepiness 
scale; BMI= body mass index; HCO3-= venous standard bicarbonate 
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Discussion and implications (papers III and IV) 
CA inhibitors, ZNS and AZT, reduced OSA severity in these randomized controlled studies and 
the effect was more pronounced after AZT. Both therapies appeared to reduce StHCO3
- and 
the BMI. The apparently lower efficacy of ZNS in terms of effects on AHI may be related to 
the different pharmacological properties of this substance. ZNS is known to have potent CA 
inhibitory properties but we cannot exclude that patients in our ZNS study were 
proportionally underdosed and did not receive equipotent dosages of the CA inhibitor267. 
There is a relative paucity of data in the literature regarding relative potency of ZNS as a CA 
inhibitor. 
An alternative explanation for the relative difference in potency between ZNS and AZT may 
be attributed to selective differences in the inhibition of CA isoenzymes300. In the context of 
chemosensory modulation of ventilation only the inhibition of CA isoenzymes II, IV and XIII 
would be expected to directly influence ventilation. Moreover, blockage of CA isoenzyme I 
and II are known to modulate erythrocyte function347,348. In remains unknown to what 
extent differences in binding characteristic may contribute specifically to the size of the 
reduction of AHI and beneficial effect on oxygenation in OSA.  
Table 9. Treatment effects of AZT on OSA or CSA reported in various studies 
 
 
 
 
 
 
 
 
 
 
The therapeutic effects of CA inhibition on OSA/CSA by AZT have previously been 
demonstrated (Table 9)49,282,283,288,289,349-352. The effect on AZT on OSA in our study coincided 
with that reported elsewhere and it is noted that the number of clinical responders among 
randomly selected OSA patients in our study was rather high. In fact, all previous studies, 
including our own, are based on rather small patient populations. Moreover, OSA, as 
described above, is known to be a disorder including multiple phenotypes. Assuming that a 
“preferential phenotype” of OSA when CA inhibition is considered would be those with a 
modified loop-gain or a low arousal threshold (see Eckert et al.2, Figure 2) it is possible that 
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our study randomly ended up randomizing a higher proportion of this type of patients. 
Hence, it may be warranted that future studies are balanced with respect to clinical 
phenotype.  
CA activity was not directly monitored in our controlled studies. However, we opted to 
assess StHCO3
- as a surrogate marker for CA activity263. Our ex-vivo data suggest that is 
associated with the degree of more extensive oxygen desaturation is associated with higher 
CA enzyme activity342. StHCO3
- was uniformly reduced after CA inhibition in our studies and 
appeared to be associated with the AHI reduction. It remains to be determined, in context of 
OSA, if there is a causal link whereby OSA induces an increase in CA activity or if, in fact, a 
proceeding increase in CA activity acts to increase OSA severity. Future studies to address 
this question may evaluate if CPAP therapy will modify CA activity (preferably assessed by 
direct measures of CA activity in whole blood). Preliminary data suggested that CPAP 
therapy had no effect on CA enzyme expression in human fat cells (a hypoxic compartment) 
from morbidly obese patients with severe OSA (unpublished data, Table 10 Figure 14). 
However, this area needs to be better explored in future studies in order to better 
understand issues related causality.   
 
Table 10. The effects of CPAP treatment on OSA and CA (II) expression (unpublished data) 
  
 
 
 
 
 
 
Figure 14. CA expression in relation to AHI at baseline (left) and change in CA expression in relation 
to the change in AHI following CPAP treatment (right) 
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Obesity is strongly associated with OSA and weight reduction is known to reduce OSA in 
most patients with moderate to severe obesity7,72. Previous studies on the CA inhibitors ZNS 
and topiramate have demonstrated notable weight reductions in obese patients during 
short to intermediate treatment periods257,272. A RCT by Winslow et al. demonstrated that a 
phentermine/topiramate combination reduced body weight along with AHI in obese patients 
with OSA256. The effects of ZNS on body composition are considered to be two-fold; it 
inhibits CA isoenzymes involved in processes related to de novo lipogenesis and modulates 
GABA and glutamatergic transmission, thus functioning as an appetite suppressant267. When 
the ZNS and AZT groups were pooled together we found that BMI decreased marginally but 
had a strong influence on the AHI reduction (data not shown) suggesting that body weight 
changes should be taken into account when the potential therapeutic effects of CA inhibitors 
in OSA are evaluated. In fact, added body weight reduction, in long-term studies, would be 
expected to add reduction of SDB in addition to that achieved in study III.  
Finally, as previously described, several CA inhibitors such as AZT are known to exhibit 
diuretics properties and to reduce extracellular fluid volume with as much as -5 to 10%326. It 
is therefore possible that that the effect of CA inhibition on OSA may be related to a reduced 
caudal to rostral fluid displacement occurring during sleep and horizontal body positioning 
as demonstrated in several publications by a Toronto based researcher group353,354. This 
effect would contribute to a relative reduction of UA size and collapsibility with a resulting 
improvement of OSA 
8.3 Association between CA activity and blood pressure  
Paper I 
Paper I addressed, among other aims, the association between a HT status as well as actual 
BP to StHCO3
- (applied as a surrogate marker for CA activity). HT was prevalent in 53.3% of 
the patients and prevalence increased with OSA severity class. StHCO3
- was higher in 
hypertensive (n=442) the normotensive (n=388) patients (24.9(2.7) and 24.1(1.9) mmol/l, 
p<0.001, respectively). The percentage of patients with a clinical HT diagnosis was 46.8, 49.8, 
54.3 and 62.7%, respectively, in the StHCO3
- quartiles (Q1 to Q4) (p=0.007). Both OSA 
severity and higher StHCO3
- were associated with a higher prevalence of HT in this 
population (both p<0.01). In a generalized linear model controlling for sex, age, BMI, 
smoking, alcohol consumption, pO2, pCO2 and apnea severity, LogStHCO3
- was independently 
associated with a clinical diagnosis of HT (β=8.0, SE 3.0, 95%CI [2.1-13.8], p=0.007).  
An additional analysis was performed to study the relationship between StHCO3
- and office 
BP. There was a weak but significant association between StHCO3
- and SBP and DBP 
(Spearman correlation, r=0.10 and 0.12, p=0.003 and <0.001, respectively). In generalized 
linear models with SBP and DBP, respectively, as dependent variables, a positive 
independent association was found between logStHCO3
- and DBP (β=27.6, SE 14.0, 95%CI 
[0.2-55.0], p=0.048) but not with SBP (β=17.1, SE 22.3, 95%CI [-26.7-60.9], p=0.45) after 
adjustment for sex, age, BMI, smoking, alcohol usage, pO2, pCO2 and apnea severity. 
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Paper II 
The association between CA activity and BP was addressed in a post-hoc analysis in paper II. 
A history of HT, other CV disease (CAD/stroke) or DM was found in 46%, 19% and 4% of 
patients, respectively. Angiotensin converting enzyme inhibitors and angiotensin II blockers, 
beta-blockers, calcium-channel blockers and diuretics was used by 17.1, 5.7, 24.3, 11.4, and 
18.6%, respectively, of the patients. 
In an analysis which accounted for all patients, irrespective of their HT status, suggested that 
CA activity was positively associated with resting diastolic BP (Pearson correlation, r2=0.142, 
p=0.001, Figure 15), but not systolic BP (p=0.098). Furthermore, CA activity was 
independently associated with DBP after adjusting for potential confounders such as sex, 
age, BMI, mean SpO2 and AHI in a generalized linear model (β=0.32, p=0.046). There was no 
interaction between use of antihypertensive medication and CA activity in relation to DBP 
(p=0.096).  
Figure 15. Relation between CA activity and sitting diastolic blood pressure 
 
 
 
 
 
 
Discussion and implications (papers I and II) 
In paper I and II, we found that increased CA activity was significantly associated with BP and 
HT status, independent of OSA. These are the first studies to establish a link between CA 
activity and BP regulation in OSA patients. Although this association does not provide any 
information on the possible causal relationships, between these two phenomena, several CA 
isoenzymes have been shown to associate with mechanisms related to BP and volume 
regulation including diuresis, fluid shift, vascular resistance and cardiac contractility307-310. 
Intermittent hypoxia has been considered as an important mechanism for HT development 
in OSA. In paper II, we found that increased CA activity was associated with the degree of 
nocturnal hypoxemia. The conventional AHI/ODI measures mainly reflect the frequency of 
SDB. It is possible that CA enzyme activity serves as a sensitive marker for hypoxic load in 
OSA patients. Increased sympathetic activity is a known hallmark phenomena in OSA 
patients. Indeed, experimental data suggest that adrenergic agonists may activate CA 
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isoenzyme I and II in erythrocytes and vascular smooth muscle tissue355. The CA enzyme 
plays a fundamental role for the bicarbonate metabolism, thus the association between CA 
activity and BP can be mirrored by bicarbonate in study I. It may be argued that the 
significant association between HT status and bicarbonate is not clinically relevant. In fact, 
the majority of the patients in paper I was within clinically defined normal ranges of 
bicarbonate [22-27mmol/L]. Hence, our studies support the notion that StHCO3
- (e.g. CA 
activity) plays a role in BP regulation rather than constituting a clinical predictor for HT in 
patients with OSA. 
8.4 Influence of CA inhibition on BP 
Paper III and IV 
Patients in paper III were included regardless of HT status and there were 6 patients with 
established HT (all on antihypertensive medication). There were no overall effects of ZNS on 
BP in the whole study group (n=13) but an ad-hoc analysis in the hypertensive subgroup at 4 
weeks showed a reduction in MAP (-4.7[-9.3 to -0.2], p<0.05). This decrease in MAP could 
primarily be attributed to an effect on SBP (-10.3 [-18.0 to -2.6], p=0.03). There was no 
change in BP in the normotensive group (n=7) and BP was not significantly changed in ZNS 
treated patients in the open arm of the study at 24 weeks. 
Paper IV included exclusively hypertensive patients with either a newly detected HT (resting 
SBP/DBP >140/90) or ongoing antihypertensive medication (1-3 medications). HT was 
generally well controlled in these patients and the mean supine SBP/DBP on previously 
prescribed antihypertensive medication was 146(14)/82(9) mmHg. Following a three week 
medication wash-out period BP had increased to 157(11)/86(11). The pressures reached at 
the end of the AZT and AZT/CPAP treatment periods were 145 (7)/81(10) and 144(7)/80(8) 
mmHg, respectively, and these pressures did not differ significantly from those obtained on 
the pre-study medication regimen.  
Both AZT and AZT/CPAP treatment significantly reduced SBP and DBP compared with 
baseline (all p<0.01) whereas SDP as well as DBP were only marginally (not significantly) 
reduced by CPAP alone (Table 11, Figure 16). There was a slight increase in supine HR in the 
AZT group but the value did not differ statistically from the other two treatment periods. The 
changes in SBP, DBP or MAP in the AZT or AZT/CPAP groups were not significantly associated 
with changes in either AHI or BMI (data not shown). 
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Table 11. Treatment effects of CPAP, AZT and AZT/CPAP on blood pressure  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. Treatment effects of CPAP, AZT and AZT/CPAP on mean arterial pressure 
 
 
 
 
 
 
 
 
 
 
 
AZT alone, or in combination with CPAP, reduced the central hemodynamic parameters 
aortic SBP, aortic pulse pressure and aortic augmentation index (all p<0.05, Table 11 and 
Figure 17) as assessed by non-invasive radial tonometry. In addition, the AZT/CPAP 
Abbreviations:SBP= systolic blood pressure;DBP= diastolic blood pressure; HR= heart rate; MAP= mean arterial 
blood pressure SBPao= aortic systolic blood pressure; PPao= aortic pulse pressure; AIXao= aortic augmentations 
index; AIXbra= augmentations index brachialis; a=p<0.05 AZT to CPAP comparison; b=p<0.05 AZT/CPAP to CPAP 
comparison  
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combination was found to reduce augmentation index in the brachial artery (p<0.02). CPAP 
treatment alone had no effect on measures of either central aortic BP or vascular stiffness. 
Figure 17. Treatment effects of CPAP, AZT and AZT/CPAP on aortic augmentation index. 
 
 
 
 
 
 
 
 
 
Discussion and implications (papers III and IV) 
Both AZT and ZNS appear to reduce office BP in OSA patients with comorbid HT and these 
antihypertensive effects were considerably stronger than those obtained by CPAP. In 
addition, data from paper IV suggest that non-invasively obtained measures of central BP 
and vascular stiffness might be beneficially influenced by AZT. However, the current study 
design precludes firm statements on whether this effect on hemodynamics was specific to 
comorbid BP elevation in OSA. It may be that similar antihypertensive effects could be 
obtained also in HT unrelated to OSA. In fact, several controlled studies in normotensives or 
hypertensive patients have not been able to demonstrate any BP reducing effect after 
AZT327,328,356,357. Nevertheless it is worth noting that CA inhibitors have been widely 
considered for potential antihypertensive properties. However, many compounds have been 
dismissed due to drug related side-effects or lack of efficacy and inferiority to novel, better 
tolerated types of antihypertensive141,. One exception is the use of thiazides in hypertension 
as this group of diuretics is known to have CA inhibitory properties141,300. 
Several experimental studies and RCTs suggest that CA inhibition by AZT may modulate 
hemodynamics specifically during hypoxic and/or hypobaric conditions. Pulmonary vascular 
resistance and vasoconstriction were reduced after AZT in animal studies320,321. Moreover 
AZT reduced BP in healthy subjects during high-altitude sojourns286,322. AZT was also shown 
to counteract excessive brachial BP elevation subsequent to acute exposure to high-altitude 
and hypobaric hypoxia in healthy volunteers325. Analogous effects during similar conditions 
have been reported in OSA patients289. Hence, there is compelling evidence linking inhibition 
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of CA activity and hemodynamic modulation in OSA. However, it should be noted that OSA is 
a condition characterized by intermittent hypoxia and that data from hypobaric/hypoxic 
conditions not necessarily may apply.  
 
Our non-invasive data suggested that the antihypertensive effect of AZT may include an 
attenuation of vascular stiffness. Other human studies using a forearm flow mode have 
demonstrated a vasodilatory response to local AZT infusion which may involve a modulation 
of calcium-activated potassium channels307. Yet other studies suggest that CA inhibition may 
induce vasodilation by modulation of nitric oxide metabolism in the vascular endothelium316, 
317. Along with this mechanism there is a relative metabolic acidosis in local tissue generated 
by CA inhibition that might lead to vasodilation318,319. It has also been proposed that  CA 
inhibitors induce a  blockade of voltage gated calcium channels313. In fact, conventional 
calcium channel blockers (e.g. verapamil and amlodipine) have been shown to reduce the 
influx of intracellular calcium, as a result of CA inhibition in erythrocytes (human data) and 
vascular smooth muscle (animal data), in a manner that results in vasodilation314,315. It 
should also be mentioned that the BP lowering effect of AZT may have been due to a diuretic 
effect326,358. Diuresis may have reduced the extracellular fluid, blood plasma volume and 
cardiac output and thereby reducing BP359.  
 
8.5 Clinical implication 
Conventionally applied therapy in OSA is, due to its mechanical character, often complex and 
cumbersome for the patient. Admittedly there is an advantage in mechanical therapies such 
as CPAP, which relates to a low number of side effects. However, compliance, as suggested 
by recent long-term protocols, may reach as low as 50% suggesting that there is a need of 
novel therapeutic strategies that not only specifically address pathogenic mechanisms in 
OSA, but also are widely tolerated by patients with the disorder.  
Current mechanical therapies in OSA do not address all aspects of comorbidities linked to 
SDB. For instance, CPAP therapy is at best body weight neutral and in fact several studies 
suggest that there is a weight increase after initiation of CPAP. The mechanism behind this 
change may be a withdrawal of apnea-related work of breathing following CPAP. CA 
inhibition, as produced in the current study, is known to induce weight loss and this effect 
may introduce a disease modifying component into OSA therapy (particularly when 
pharmacological therapy is combined with CPAP in overweight OSA patients) 
A similar reasoning may apply to the control of CV morbidities such as HT in OSA. The 
current results suggest that high CA activity may constitute a specific mechanism for BP 
elevation in OSA and that BP may be potently reduced by CA inhibition in these patients. It 
remains to be explored if various forms of HT are equally responsive for CA inhibition in OSA 
or if HT in response to elevated CA activity represents a specific phenotype in OSA. 
Nevertheless, CA inhibition introduces a possibility for a disease modifying therapy in OSA-
related HT. 
Yet another implication of the current research is the possibility to identify a novel and 
specific biomarker in OSA. The apparent dose-related association between OSA and CA 
activity suggests that a development of a biomarker may be feasible. Bicarbonate was used 
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as a surrogate marker of CA activity in the current study and has been considered as a state 
as well as a trait marker in patients with more severe hypoventilation states such as the 
OHS. Our studies suggested a considerable variability in the CA-activity marker at any given 
level of AHI. However, it is possible that markers of CA activity better reflect the state of 
various physiological functions in OSA than does the AHI or similar markers of SDB. 
It may be concluded that the current studies outline one of the first systematically evaluated 
potential pharmacological therapies in OSA. Future studies in this area will need to focus on 
how this therapeutic principle may be optimized in terms of improved patient selection, 
adaptation to key pathophysiological mechanisms and selection of ideal drug candidates. 
8.6 Study limitations 
Paper I 
SDB was assessed with a contemporary polygraphy recording device on two consecutive 
nights in order to reduce the potential effect of an inaccurate AHI value due to first night 
effect or night-to-night variability. Weaknesses include a lack of quantitative data on 
overnight hypoxic events like oxygen desaturation in the multivariate analyses. However, 
nocturnal hypoxic exposure was captured as 4% oxygen desaturation events that were used 
for computation of the AHI. Another weakness in this study is the lack of detailed 
information on the type of antihypertensive medication. Also, it cannot be excluded that 
prescribed antihypertensive medication, e.g. diuretics such as hydrochlorothiazide, may 
have influenced the association between StHCO3
- and BP although the influence of thiazides 
on StHCO3
- is likely to be very limited. Finally, the cross sectional design of our study did not 
allow any firm conclusions regarding the causality of the demonstrated associations.  
Paper II 
Our study population was a clinical cohort and a there was no control group in the data 
analysis. Blood gas assessments were not performed in the study and we could therefore not 
evaluate out CA-activity method in relation to a bicarbonate value. Furthermore, the cross-
sectional design in this study did not allow us to draw any conclusions on the causality of the 
association between apnea severity and CA activity. Future studies that evaluate the 
elimination of OSA by CPAP are needed to better address this issue. It cannot be excluded 
that ongoing medication may have affected CA activity. However, an analysis controlling for 
the use of diuretics did not suggest that this was the case. Our analysis method only 
permitted assessment of total CA activity in whole blood. It remains unknown whether OSA 
was associated with alteration of specific CA isoenzymes or a change of CA activity in other 
compartments of the body. Finally, due to a change of clinical routines, haemoglobin data 
was only available in a subgroup of patients. However, our subgroup analysis suggested that 
the association between CA activity and apnea severity was independent of haemoglobin 
concentration. 
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Paper III 
Study limitations include a failure to reach the pre-set patient number prior to the study 
drug expiry date and due to recruitment difficulties. The initial power calculation indicated a 
minimum of 90 patients but only 42 were finally included in the study. However, the study 
hypothesis was verified in spite of the lower number of participants. We set out to prove the 
effects of ZNS in unselected OSA patients and therefore no particular attempts were made 
to optimize weight reduction or to characterize specific phenotypic traits in the study 
population. Furthermore, another limitation in the study concerns the fact that CA-activity 
was not assessed. Despite an adequate randomization procedure the patients in the CPAP 
group were younger than the ZNS group at baseline. Twenty percent of the ZNS patients 
reported dysphoria as a side-effect at 24 weeks, although there was no difference at 4 weeks 
compared to placebo.  
Paper IV 
The major limitation of the study was that CA activity was not directly assessed. Instead, 
StHCO3
- was used as a surrogate marker and other physiological mechanisms involved in 
StHCO3
- metabolism may have influenced the result. The power calculation in this study was 
30 patients. Hence, we managed to recruit only 14 patients and this caused several of the 
analyses to be performed in a potentially underpowered study. PSG was not performed and 
the severity of the breathing disorder may have been underestimated. This study included 
hypertensive patients with OSA but not those without. Hence, it is possible that the effects 
recorded in the study are generic to HT rather than specifically linked to HT in OSA. Finally, 
this was a cross-over study with the possibility of a carry-over effect between treatment 
periods. However, we were not able to identify such effects after statistical evaluation of the 
data and the treatment order was randomized.  
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9 Conclusion and future perspectives 
The current studies suggest that mechanisms related to CA activity may have important 
implications for the development and maintenance not only of SDB but also comorbid 
conditions such as CV complications and obesity in OSA. In that sense our data identifies a 
novel potential mechanism for HT development in OSA. We also identify a potential 
pharmacological principle for treatment of at least a subgroup of patients with OSA. Future 
studies are needed to determine the relative importance of this mechanism in the treatment 
of OSA and if a CA activity related principle may be used to tailor an effective therapy. The 
prospect of such a therapy is that of a disease modifying principle and in this respect it 
would provide an improvement on top of currently available therapeutic alternatives. 
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